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CHAPTER 1  
General introduction 
1. Introduction 
   With the rapid development of recombinant DNA technology a broad variety of 
protein drugs has become available for therapy of a wide range of conditions, 
including various cancer types, heart attack, stroke, cystic fibrosis, Gaucher's disease, 
diabetes, or anaemia, haemophilia [1, 2]. Compared to small-molecule drugs that still 
account for the majority of the pharmaceutical market share, proteins are more 
specific, which may result in less side effects and lower toxicity [3, 4]. The 2013 
Pharmaceutical Research and Manufacturers of America (PhRMA) report on “Biologic 
Medicines in Development” claimed that over 900 kinds of protein and 
peptide-based medicines are in development, aiming at treating more than 100 
diseases, of which 353 candidates target cancer and related conditions, 187 
infectious diseases, 69 autoimmune diseases and 59 cardiovascular diseases [5]. It 
has been estimated that the global therapeutic proteins market worth 113.4 billion 
dollars in 2016 and will increase up to 141.5 billion by 2017 [6].  
   Proteins are large amino acid based macromolecules characterized by a unique 
three-dimensional structure corresponding to their biologically active state [7]. The 
native structure of a protein molecule is the result of a fine balance among various 
interactions including covalent linkages, hydrophobic interactions, electrostatic 
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interactions, hydrogen bonding and van der Waals forces [7]. This specific structure is 
rather sensitive and formulation of proteins with optimal efficacy and safety needs 
special attention to external factors such as pH, temperature, and surface interaction, 
as well as contaminants and impurities of excipients affecting chemical and physical 
stability [4]. 
2. Parenteral administration of protein drug 
   Although non-parenteral routes benefit from convenience and patient 
acceptability, they exhibit low bioavailability of proteins and peptides [8]. Permeation 
enhancers, enzyme inhibitors and special formulation vehicles have been tested but 
still currently, no clinically useful oral formulations have been established [9].  
   Therefore, subcutaneous and intravenous injections are the most common form 
of protein administration [4]. Many therapeutic proteins have a short in vivo half-life 
and treatment of chronic diseases necessitates frequent injections [7]. An attractive 
way to overcome this problem would be a dosage form that delivers the proteins 
over a longer period rendering plasma concentrations within the therapeutic window 
for an extended time. Such sustained release formulation would provide numerous 
and distinct advantages, both therapeutic and financial, including protecting protein 
from clearance, improving ability of delivering the protein locally to a particular site 
or body compartment, and increasing patient comfort, convenience, and 
compliance [10]. In fact, parenteral sustained release systems are relatively mature 
for delivering small molecular drugs. The difficulty of developing similar delivery 
systems for proteins mainly results from protein instability during manufacturing but 
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additionally the protein must remain stable after administration at body temperature 
in these systems for weeks or months [4]. These challenges have necessitated new 
materials and methods to achieve parenteral depot formulation for protein drugs. 
3. Materials for parenteral protein drug delivery 
   Materials used for parenteral protein drug delivery must be at least non-toxic and 
biocompatible and a broad number of natural and synthetic polymers, lipids and 
silica materials have been applied [11-17].  
3.1. Natural polymers 
   Among the natural polymers, polysaccharides and proteins are common carrier 
materials used in the parenteral depots of protein drugs [17, 18]. The 
polysaccharides have abundant resources from algal origin (e.g. alginate), plant origin 
(e.g. pectin, guar gum), microbial origin (e.g. dextran, xanthan gum), and animal 
origin (hyaluronic acid, chitosan, chondroitin) as well as low cost in their 
processing [19]. Furthermore polysaccharides can be easily modified chemically and 
biochemically due to the presence of various groups on the polymer chain which can 
be derivatized, leading a broad variety of polysaccharide derivatives which are used 
for sustained release application [19]. Protein e.g. gelatin, collagen, albumin or fibrin 
are another promising class of materials [20]. They are degraded by the normal 
protein turnover pathways and are in general biocompatible and biodegradable 
which makes them attractive for biopharmaceutical drug delivery [20]. Among all the 
natural polymers, alginate, hyaluronic acid, chitosan and gelatin are the most popular 
carrier materials for protein drug delivery. 
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   Alginate, an anionic polysaccharide extracted from various species of algae, 
consists of D-mannuronic and L-guluronic acid units. The ratio and distribution of 
D-mannuronic and L-guluronic acids determines the functionality of alginate as 
carrier material [11]. Aqueous alginate solution dropped into a calcium bath gel by 
rapid crosslinking between the alginate guluronic acid units and the cation [11]. Due 
to the simplicity, non-toxicity, biocompatibility, low cost and mild formulation 
conditions, alginate has been fabricated into large beads, microbeads, block gels, 
fibers, and used for in situ gelling systems for the entrapment and/or delivery of a 
variety of proteins [21-23]. Factors such as alginate concentration, cation 
concentration, hardening time, viscosity of alginate solution have been 
investigated [22]. Despite the broad use of ionically cross-linked alginate hydrogels, 
the systems usually lead to poor control over the swelling behavior and the 
mechanical properties of gels. Additionally, due to the loss of cations under 
physiological conditions, ionically cross-linked alginate hydrogels exhibit limited 
long-term stability and release [24]. 
   Hyaluronic acid (HA), a linear polysaccharide of a wide molecular weight range 
(103-107 Da), consists of alternating disaccharide units of D-glucuronic acid and 
N-acetyl-D-glucosamine with (1→4) inter glycosidic linkage and is distributed 
throughout the extracellular matrix, connective tissues, and organs of all higher 
animals [25, 26]. Due to its strong hydration, viscoelasticity and high biocompatibility, 
it has received great attention for protein drug delivery system development [23, 27]. 
Natural HA is highly hydrated and rapidly degraded, which constraints its application 
in prolonged release formulations. An efficient method to offset its deficiencies is to 
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chemically modify HA [28]. The pore size of HA hydrogels can be controlled by 
changing the crosslinking density for the encapsulation of protein drugs within the 
HA hydrogel networks [23, 29]. However, protein drugs were released rapidly within 
a week due to the difficulties in the preparation of highly crosslinked HA hydrogel 
network and preserving injectability in many cases [29]. 
   Chitosan is another polysaccharide consisting of varying amounts of 
(1-4)-glycosidic bonds linking glucosamine and N-acetyl-D-glucosamine [30]. It is 
made by alkaline treatment of chitin from shells of shrimp and other crustaceans [31]. 
With its different functional groups it allows versatile chemical modification [30]. 
Compared to many other natural polymers, chitosan carries positive charge under 
physiological conditions which makes it a preferred candidate for drug encapsulation 
and controlled release of negatively charged compounds [32]. A broad variety of 
chitosan based protein drug delivery systems in the forms of gels and particles have 
been developed and studied [31, 33]. As a result of the combined effects of hydrogen 
bonds and hydrophobic interaction, chitosan tends to form aggregates making it 
difficult to dissolve in the neutral media, which poses a substantial limitation [32].  
   Gelatin is obtained by hydrolysis of collagen, which is a fibrous biomaterial 
typically derived from skin, tendon and in connective tissues of animals [34]. The 
high number of amino and carboxylic groups enable an easy crosslinking of gelatin 
with a variety of crosslinkers. The isoelectric point of gelatin can be modified during 
the fabrication process to yield either gelatin which is either negatively or positively 
charged at physiological pH. This allows substantial electrostatic interactions 
between a charged biomolecule. Various forms of gelatin carrier matrices can be 
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fabricated for controlled release studies [13]. In spite of these advantages, gelatin is 
still limited due to its high degree of swelling in aqueous environments leading to fast 
drug release in the body. Swelling and degradation can be reduced by chemical cross 
linking e.g. by glutaraldehyde or formaldehyde treatment giving rise to the formation 
of non-soluble networks. However, the use of cross linkers can lead to reduced 
biocompatibility, due to the presence of residual cross linking agent and to unwanted 
reaction between drug and cross-linker [35]. 
3.2. Synthetic polymers 
   Synthetic polymers like aliphatic polyesters and polyanhydrides have also been 
extensively studied for the protein drug delivery [36, 37]. Their biodegradation is the 
result of cleavage of labile bonds by a non-enzymatic hydrolytic process. Among 
aliphatic polyesters, the bulk erodible polylactic and polyglycolic acid based 
polyesters (PLGA) have been most commonly investigated [14]. During protein 
release from PLGA systems, deleterious effects including an acidic microenvironment 
and strong hydrophobic interactions occur, which are significant sources for 
irreversible physical and chemical inactivation of protein drugs [38]. Polyanhydrides 
differ from polyesters in their erosion mechanism as they exhibit surface erosion, 
which may prevent covalent aggregation by reducing water penetration into the 
device. However, these materials are more hydrophobic enhancing interactions 
between polymer and protein, which may result in non-covalent aggregation [36]. 
3.3. Lipids 
   The term lipids refer to a family of products with diverse physical and chemical 
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properties, including e.g. oils, fats, waxes and fatty acids, triglycerides and 
phospholipids [39]. The lipids exhibit tremendous variety in acid chain length and 
saturation and can be relatively easily formed into particles or implants, facilitating 
the design of the desired release profile [40]. They are degradable and generally 
recognized as safe [41]. Triglycerides as an important representative revealed great 
potential for the controlled release of protein drugs. Their use for the preparation of 
implants, microparticles or nanoparticles has shown good results for the 
incorporation and sustained release of proteins [42-52]. Triglyceride matrices avoid 
the pH-changes occurring with PLGA materials which are critical for protein drugs [41, 
53, 54]. The drug release mechanism differs from the commonly used polymers. It is 
mainly controlled by diffusion of drug molecules through aqueous pores created by 
the release buffer upon penetration into the matrix and dissolution of water soluble 
drugs, which is neither accompanied by hydrolysis-induced erosion nor by swelling 
phenomena [55]. This makes lipid materials a promising candidate as an alternative 
material to the polymers for the design of parenteral protein drug delivery systems. 
3.4. Silica 
   Mesoporous silica has become a promising drug vehicle due to its unique 
mesoporous structure, high surface area, large pore volume, tunable pore diameter 
and narrow pore size distribution [56]. The silica materials cause no adverse tissue 
reactions and may become slowly degraded [57-60]. The features of high chemical 
and thermal stability, surface functionality and biocompatibility contribute to the 
controlled release and target drug delivery of drugs [61, 62]. The pores within the 
silica take on host molecules, sheltering them from the external environment until 
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unloading conditions are met. The majority of drug release from silica is controlled 
by the diffusion of drug molecules through the pores within the silica and 
simultaneous matrix degradation whereas silica materials do not swell in water [58, 
62]. This functionality has proven particularly useful in the delivery of small drug 
molecules [63]. Small proteins with hydrodynamic diameters less than the pore size 
can also be loaded and delivered [64]. However, entrapment of large molecular 
weight proteins in the silica gel for parenteral application has been rarely explored. 
Thus, the incorporation of large molecular weight proteins into mesoporous silica is 
of high interests. 
4. Parenteral sustained release systems for proteins 
   In virtue of the advantages of triglycerides and silica materials they have been 
widely recognized as attractive carriers for protein drug delivery in parenteral 
application. Various types of sustained release systems can be designed for protein 
drug delivery based on the triglycerides or silica materials. The most commonly used 
systems are implants, nanoparticles and microparticles.  
4.1. Implants 
   Due to poor water solubility and harsh processing conditions of conventional 
precursors, silica implants are mainly applied for the small molecule delivery [65, 66]. 
But incorporation of protein drugs in triglycerides implants has been developed for 
long-term release application over days to months [45-50, 67-69]. Lipid implants are 
usually prepared using direct compression, hot melting extrusion, injection molding 
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or compression molding [46, 67, 70]. The use of organic solvents can be avoided. No 
water/organic solvents interfaces are created, which might affect protein integrity. As 
a result of implantation, a tissue response may occur in the form of an encapsulation, 
or the development of tissue edema or inflammation. In addition, granuloma 
formation or increased vascularization may occur [71]. Furthermore, if surgical 
resection is to be avoided after drug exhaustion, complete biodegradability has to be 
guaranteed in vivo [72]. 
4.2. Nanoparticles 
   Mesoporous silica nanoparticles as a drug delivery agent have been explored in 
the past two decades but they have only recently been further modified as a 
potential agent for the delivery of proteins [61, 62, 64, 73]. Emulsion chemistry is 
commonly used to prepare silica nanoparticles [74]. The mesoporous structure 
makes them ideal nanovehicles for protein delivery and release because of their 
large pore volume ( ≈1 cm3 g-1) and tunable pore diameters (2-10 nm), which allows 
for the loading of substantial amounts of protein [62]. However, the pore size of 
typical mesoporous silica nanoparticles is the limiting factor for the effective delivery 
of proteins in particular. Although the pores can be expanded to accommodate larger 
host molecules, there still remains a size limit. Only small proteins can be successfully 
loaded, since larger ones may not ﬁt in the pores [61, 62]. 
   It has been demonstrated that the physicochemical parameters of lipid-based 
nanoparticles (size, surface charge, morphology, surface chemistry, stability) may 
easily be adjusted as to satisfy the requirements for improved drug safety, 
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appropriate drug release kinetics, and possibility for scaling-up manufacturing [75].  
Preparation methods for lipid nanoparticles include high-pressure homogenization 
(hot and cold homogenization), solvent emulsification/evaporation, and 
microemulsion techniques [76]. In those methods, lipid usually requires high 
temperature, high pressure, organic solvent or ultrasound, which may lead to protein 
drug denaturation [77]. Additionally, incorporation of sufficient amounts of drug is 
troublesome due to the hydrophobic nature of the lipids [78]. 
4.3. Microparticles 
   Compared to silica implants and nanoparticles, microparticles provide enhanced 
flexibility in both fabrication methods and release rate. Currently, many techniques 
are available for the manufacturing of silica-based microparticles such as 
emulsification-solvent evaporation, solvent displacement, self-assembly systems, 
supercritical fluid processing or spray drying [79-81]. The larger size of mesopores 
offers silica microparticles with highly accessible internal surface areas for high 
loading with large protein drugs. The release rates can be controlled by tailoring the 
internal structure of the microparticles for a desired release profile based on size of 
protein drugs. An ideal microparticle formulation should have reasonably high yield, 
drug-loading capacity and efficiency, stable protein structure, adjustable release 
profiles, low burst release and provide sustained release of biologically active 
proteins [79, 80]. Spray drying has been implemented commercially and offers the 
advantages of rapid production, controllable particle size, shape and density, all 
crucial features with regard to drug delivery [82]. Recently, spray-drying technology 
has been successfully applied for different heat-sensitive protein drugs due to fast 
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drying (seconds or milliseconds) and relatively short exposure time to heat [83-86]. 
Silica-based microparticles incorporating protein drugs have also been synthesized 
via self-assembly of surfactants followed by solvent extraction or calcination of the 
templating agents [16, 87, 88]. However, the protein drug-loaded silica microparticles 
fabricated by spray drying for sustained release application are rather unexplored. 
Hence, in this study, a new silica precursor (TMEOS) exhibiting high compatibility 
with protein drugs is presented to produce microparticles for sustained release 
application. 
   Due to better biodegradability, less tissue response, higher drug loading and 
flexible fabrication methods, lipid microparticles have been recognized as a 
potentially more suitable and preferred sustained release system compared to lipid 
implants and nanoparticles. They can be prepared through melt emulsification, 
solvent emulsification-evaporation, solvent emulsification-diffusion, double emulsion 
(w/o/w), spray congealing, supercritical fluid-based methods spray drying or fluid 
bed coating [54]. Fluid bed coating has been widely used to achieve a desired release 
profile in pharmaceutical products for many years because the process can be 
applied for coating cores of various sizes starting from small particles (theoretically 
50 μm) to considerably large size objects like tablets and capsules (few 
centimeters) [89]. The process is characterized by the high drug loading capacity and 
efficiency, as well as the intensive heat and mass transfer between the gas stream 
and the solid particles. This comes with an efficient drying or coating which enable 
moderate temperatures to avoid damage of sensitive protein drugs [89]. The drug 
release properties can be tailored by changing of coating material and level [90]. 
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These features make fluid bed systems particularly suitable for producing 
protein-loaded microparticles for sustained release application with functional 
coating. The development of microparticles with lipid coating keeps special 
challenges due to the extremely small size of particles and the tackiness of the lipid. 
The most commonly used method is hot melt coating process [91]. But protein drugs 
may be degraded at higher temperature since the coating agents normally used in 
hot melt coating have high melting points [92]. This problem can be overcome with 
organic solvent spray coating method as the process temperature is much lower. But 
the use of organic solvent bares a higher risk of residual solvents which also lead to 
protein damage. Therefore, this study is to investigate the possibility of using organic 
solvent spray coating to form the lipid-coated microparticles without agglomeration 
at modest temperature for sustained drug release of protein drug in a fluid bed 
coater. 
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CHAPTER 2  
Objectives of the thesis 
   Many protein drugs exhibit short half-lives in vivo and multiple dosing schemes 
and frequent injections are necessary to achieve therapeutic drug levels, which 
results in poor patience compliance. Due to the good biocompatibility of triglycerides 
and silica materials, the objective of this work was to develop protein loaded 
microparticles for sustained release application based on triglycerides and silica 
(TMEOS) carriers. It included two main parts, which were lipid coating of protein 
carrying beads in a fluid bed coater and silica particle fabrication via spray drying. 
Particular goals were: 
a)  to optimize the parameters for the lipid coating of microparticles in the fluid bed 
coater and to achieve a sustained release of model drugs over weeks as well as to 
investigate the effects of coating level, lipid type, size of starter bead and drug type 
on model drug release (chapter 3);  
b)  to stabilize IgG1 during spray loading of the initial starter beads and to control its 
sustained release by varying lipid type and coating load, while ensuring the stability 
of IgG1 after release (chapter 4); 
c)  to understand gel formation by TMEOS and to optimize the parameters for silica 
microparticle preparation as well as to fabricate the silica microparticles by spray 
drying. Subsequently a sustained release of  high molecular weight model 
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compound was to be achieved and the effects of amount and molecular weight of 
additive as well as pH of precursor solution on drug release profile were to be 
analyzed (chapter 5); 
d)  to investigate the compatibility of TMEOS with IgG1 and lysozyme, and study the 
effects of additive on the protein release profile (chapter 6). 
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CHAPTER 3  
Formation of polyol core microparticles 
for sustained release with lipid coating 
in a mini fluid bed system 
Abstract 
   Biodegradable polymeric materials for parenteral controlled release systems are 
associated with various drawbacks for biopharmaceuticals. Sustained delivery 
system based on lipids such as implants or microparticles present an interesting 
alternative. The goal of this study was to prepare sustained release microparticles 
for methyl blue and aspartame as sparingly and freely water-soluble model drugs by 
lipid film coating in a Mini-Glatt fluid bed, and to assess the effect of coating load of 
two of lipids, hard fat and glyceryl stearate, on the release rates. 30 g drug-loaded 
mannitol carrier microparticles with average diameter of 500 or 300 μm were coated 
with 5 g, 10 g, 20 g and 30 g lipids, respectively. The model drugs were completely 
released in vitro through pores which mainly resulted from dissolution of the polyol 
core beads. The release of methyl blue from microparticles based on 500 μm carrier 
beads extended up to 25 days, while aspartame release from microparticles formed 
from 300 μm carrier beads was extended to 7 days. Although glyceryl stearate 
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exhibits higher wettability, burst and release rates were similar for the two lipid 
materials. Polymorphic transformation of the hart fat was observed upon release. 
The lipid-coated microparticles produced with 500 μm carrier beads showed slightly 
lower burst release compared to the microparticles produced with 300 μm carrier 
beads as they carried relatively thicker lipid layer based on an equivalent lipid to 
mannitol ratio. Aspartame microparticles showed a much faster release than methyl 
blue due to the higher water-solubility of aspartame. With the present study 
appropriate formulation and manufacturing parameters for the design of sustained 
release microparticles by lipid coating in a mini fluid bed were established, which 
could subsequently be transferred to biopharmaceuticals.  
Keywords: Methyl blue, Aspartame, Mannitol, Hard fat, Glyceryl stearate, Fluid bed 
coater, Microparticles, Sustained release, Lipids, Coating 
 
 
 
 
 
 
 
 
 
CHAPTER 3 FORMATION OF POLYOL CORE MICROPARTICLES WITH LIPID COATING 
22 
 
1. Introduction 
   Many biopharmaceutical drugs require frequent parenteral administration to 
guarantee a therapeutic level due to their short half-live in-vivo, which leads poor 
patient compliance. Consequently, sustained release formulations are of high interest 
[1-3]. For the parenteral sustained release of biopharmaceuticals, the most 
commonly used carrier materials are polylactide (PLA) and poly(lactide-co-glycolide) 
(PLGA) since they can provide sustained release for a range of times from days up to 
months and are well established for small molecule and peptide drugs[4, 5]. However, 
lactic and glycolic acid result upon PLGA degradation, leading to an increase in 
osmotic pressure and a significant pH drop within the micro-environment, which can 
result in a loss of activity with biopharmaceuticals [6, 7]. Additionally, harsh 
microparticle manufacturing conditions like high temperature, high shear forces and 
organic solvent, may result in detrimental effects on the structure and the activity of 
protein drugs [6, 7]. Triglycerides, which are Generally Recognized As Safe (GRAS), 
biocompatible, biodegradable and not inherently immunogenic [8], have been 
successfully used to control sustained release of proteins in form of implants, 
nanoparticles, as well as microparticles, which are the most suitable and preferred 
system till today [9-17]. 
   Fluid bed coating for microparticle preparation has been widely used in 
pharmaceutical industry to control oral drug release [18, 19]. The most widespread 
coating materials, cellulose and polyacryl acid derivates are hardly appropriate for 
parenteral drug delivery systems as they are not biodegradable or available at 
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adequate quality . An interesting alternative is to utilize lipid coated microparticles as 
parenteral controlled delivery systems. Lipid film coatings provide several 
noteworthy advantages: (i) they are plastically deformable and form homogenous 
films without cracks during the coating process; (ii) the amount of excipient required 
is generally appropriate; (iii) usually only one lipid is required simplifying the 
formulation and hence the registration of the drug product with regulatory 
authorities; and finally (iv) they are relatively inexpensive [8, 20, 21]. 
   Typically, hot-melt and organic solvent spray coating are used for lipid coating [21, 
22]. Both high temperature and organic solvent may be critical for use with sensitive 
biopharmaceutical drugs. In general, also the amount of coating that can be 
deposited on the surface of the smaller cores compared to oral dosage forms is 
limited [21, 23]. Furthermore, sustained release microparticles are normally 
suspended in a suitable vehicle and injected by using a conventional syringe with a 
18 or 20 G gauge needle, which requires free flowing microparticle powders of less 
than 250 μm in diameter, ideally less than 125 μm [24]. Lipid coating of such small 
microparticles is challenging due to the high tendency to agglomerate upon coating 
with the tacky lipid [25]. Additionally, a small scale process is required for 
development due to the high costs of protein drugs. Consequently, a new small scale 
lipid coating process with the potential for manufacturing of sustained release 
microparticles for biopharmaceutical drugs is highly desirable. 
   The main objective of this work was to investigate the possibility of using organic 
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solvent fluid bed spray coating to form the lipid-coated microparticles without 
agglomeration at modest temperature for sustained drug release. Successful loading 
of polyol and sugar spheres with protein drugs has been demonstrated before and 
this renders a mini fluid bed system very interesting for loading and lipid coating of 
starting beads [26]. Mannitol beads were selected as the carrier core providing high 
water solubility and biocompatibility. Drug release from the lipid-coated 
microparticles may occur through pores in the coat, which form upon dissolution of 
the polyol core beads. The target release profile was expected to reach a few weeks. 
Two kinds of lipids with different lipophilicity and wettability, hard fat (HF) and 
glyceryl stearate (GS) were tested. Furthermore, the effect of the core bead size on 
processing and release was studied. Two model compounds, methyl blue (MB) and 
aspartame (ASP) with different solubility were loaded to investigate the effect of drug 
type on the release. The resulting process parameters could be subsequently 
transferred to protein loaded core beads. 
2. Materials and Methods 
2.1. Materials 
   Pearlitol® 500DC-Mannitol and Pearlitol® 300DC-Mannitol (MAN) were kindly 
provided by Roquette Corporate, Darmstadt, Germany. Methyl blue (MB) and the 
reagents used for MAN determination were purchased from Sigma-Aldrich, Munich, 
Germany. Aspartame (ASP) was kindly provided by Salutas Pharma GmbH, Barleben, 
Germany. Witepsol® E85 (hydrogenated coco-glycerides, HF) and Imwitor® 900 
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(glyceryl stearate with a monoester content of 40–55%, GS) were kindly provided by 
Sasol GmbH, Hamburg, Germany. Isopropanol (99.7%) was supplied by the reagent 
center of the University of Munich, Germany. 
2.2. Methods 
2.2.1. Preparation of drug-loaded starting cores 
   0.45 g MB or 1.50 g ASP was dissolved in 45 mL or 150 mL deionized water to get 
the model drug solution (1.0%, W/W). 30 g MAN microparticles were loaded with the 
model drug solution in the Mini-Glatt fluid bed (Wurster insert, Glatt GmbH, Binzen, 
Germany). The detailed operation conditions were as follows: Tinlet: 40 °C; 
Pprocess: 1.0 bar; Patomizing air: 1.0 bar; spray rate: 1.0 mL/min; spray nozzle 
diameter: 0.3 mm. After coating, the microparticles were dried for additional 15 min 
at 40 °C in the fluid bed. 
2.2.2. Preparation of lipid-coated microparticles 
   Lipid was dissolved at 2% w/v in hot isopropanol (70 °C). 30 g drug-loaded 
microparticles were coated with the lipid solution in the Mini-Glatt fluid bed at: 
Tinlet: 40 °C for GS and 30 °C for HF; Pprocess: 0.7 bar; Patomizing air: 0.5 bar; spray 
rate: 7.0 mL/min; spray nozzle diameter: 0.5 mm. After coating, the microparticles 
were dried for additional time of 15 min at the same conditions. 
2.2.3. Determination of drug loading of lipid-coated microparticles 
   200 mg of lipid-coated microparticles were dispersed in 50 ml of hot deionized 
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water (70 °C). Approximate 3 mL slurry was filtered through a 0.2 μm filter to remove 
the lipid after it was cooled down to room temperature. Filtrate was analyzed for 
drug content present at a 588 nm for MB and 258 nm for ASP using an Agilent 8453 
UV-Vis spectrophotometer (Agilent, Waldbronn, Germany). Each experiment was 
performed in triplicate. 
2.2.4. Microparticle morphology 
   The morphology of microparticles was analyzed with a light optical microscope 
(Olympus BX50 F4, Olympus, Tokyo, Japan) equipped with a digital camera (HVC 20, 
Hitachi, Maidenhead, GB). Additionally, the microparticles were visualized by 
scanning electron microscopy (SEM) using a Jeol JSM-6500F instrument (Jeol Ltd., 
Tokyo, Japan) with Inca Software (Oxford instruments, Oxfordshire, UK). 
2.2.5. Mannitol determination  
   The MAN release was determined by a colorimetric method [27]. 10 μL release 
medium was diluted with 990 μL deionized water, mixed with 1 mL potassium 
periodate (0.015 mol/L in 0.12 mol/L HCl solution), incubated for 10 min at room 
temperature, and reacted with 2 mL 0.1% L-rhamnose and 4 mL Nash reagent. The 
mixture was placed in a water bath at 53 °C for 15 min. After cooling to room 
temperature the MAN content was quantified at 412 nm using an Agilent 8453 
UV-Vis spectrophotometer. Each experiment was performed in triplicate. 
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2.2.6. In vitro release 
   In vitro release was studied in phosphate buffer saline (PBS, pH=7.4) in 37 °C 
water bath with constant shaking at 30 rpm (Julabo SW21, Julabo GmbH, Seelbach, 
Germany). Approximate 1.0 g of drug-loaded microparticles suspended in 3 mL 
buffer were transferred into a dialysis bag with 12 kDa cutoff which was sealed and 
immersed into a 50 mL disposable plastic tube with 37 mL of phosphate buffered 
saline release medium containing 0.01% NaN3. At designated time points, 1 mL 
release medium was withdrawn and replaced with the same amount of fresh release 
medium. The model drug content in the release medium was quantified as described 
above. Each experiment was performed in triplicate. 
2.2.7. Differential scanning calorimetry (DSC) 
   Differential scanning calorimetry (DSC) analysis was performed using a Mettler 
DSC 821e (Mettler Toledo, Giessen, Germany). DSC scans were recorded at a heating 
and cooling rate of 5 °C/min. The samples were weighted in 40 μL aluminium pans 
and cooled down from 25 °C up to 0 °C, kept for 2 mins at 0 °C, heated up to 110 °C, 
kept at 110 °C for 3 mins, cooled again down to 0 °C, kept for 2 mins at 0 °C and 
reheated up again to 110 °C, kept at 110 °C for 3 mins, cooled down to 25 °C. 
3. Results and Discussion 
3.1. Methyl blue release from HF-coated microparticles  
   The lipid-coated microparticles prepared in this study consisted of a MAN starter 
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core coated with a model compound and subsequently a lipid layer for sustained 
release of different thickness. To study the influence of the amount of lipid coat on 
the release of MB, 30 g drug-loaded MAN microparticles were coated with 5 g, 10 g, 
20 g or 30 g HF. The lipid-coating of MAN microparticles is illustrated in Fig. 1. The 
uncoated microparticles were irregular in shape (Fig. 1a). The model drug MB 
migrated into the carrier beads exhibited a homogeneous loading (Fig. 1b), 
potentially reducing the contact with organic solvent during the lipid coating process, 
which is very important for biopharmaceutical drugs. The drug loaded microparticles 
subsequently coated with lipid maintained their original shape with only minimal 
agglomeration (Fig. 1c).  MB diffusion into the retarding lipid coat was not 
observed (Fig. 1d), which may be beneficial to keep potential burst release low 
  
  
(a) (b)
) 
(c)
) 
(d)
) 
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Fig.1. Microscopic images of lipid coating of MAN microparticles, (a) starting MAN 
beads; (b) MB-loaded microparticles; (c) 30g HF-coated microparticles; (d) cross 
section of 30g HF-coated microparticle 
   Fig. 2a shows the MB release profiles from microparticles coated with different 
amounts of HF. The microparticles coated with 5 g HF show a high burst release of 
around 50% followed by subsequent MB release over 14 days. More HF lowers the 
burst and the release rate. The release period is prolonged to 25 days by coating with 
30 g HF. The deceleration of release is also found the MAN core material (Fig. 2b). In 
general, MAN shows much higher burst and a faster release than MB. Nearly all MAN 
is liberated within 1 day from microparticles coated with 5 g HF, while the release is 
extended to 10 days upon coating with 30 g HF. This is consistent with the particle 
morphology after release (Fig. 3). Almost all of the microparticles coated with 5 g HF 
are collapsed after the release while this is the case for only a small portion of 
microparticles coated with more lipid. 
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Fig.2. MB (a) and MAN (b) release profiles of microparticles coated with different 
amounts of HF 
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Fig.3. SEM photographs of MAN particles coated with 5g (a), 10g (b), 20g (c) and 30g 
(d) HF before (left) and after (right) release 
   For the lipid-coated microparticles, Fickian diffusion is the underlying drug 
release mechanism, where water: (i) penetrates into the matrix, (ii) dissolves the 
MAN and drug, (iii) occupies the pores generated by the diffusion of dissolved MAN 
and drug and (iv) creates channels which enhance matrix porosity and drug mobility, 
allowing for continuous MAN and drug diffusion out of the microparticle and into the 
release medium [8]. Microparticles with thin lipid layer became hollow with the 
dissolution and diffusion of MAN upon contact with the release medium and 
subsequently collapsed, inducing the burst release. In contrast, microparticles with 
thick lipid layer maintained their geometry during the release process even after the 
core MAN was gone, which resulted in sustained drug release. The lipid film 
thickness of microparticles is influenced by the size and mass distribution of beads in 
a fluid bed apparatus equipped with a Wurster column. Based on different velocities 
and fluidization patterns of the various size beads, the larger and heavier beads 
within a batch coated by this method receive a thicker film and therefore display a 
(d1) (d2) 
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significantly slower release rate when compared to smaller and lighter beads [28].  
   The highly water soluble MAN (182 g/mol, Swater = 216 g/L) [29] present at large 
quantities in the core acted as pathbreaker. Its dissolution and diffusion resulted in 
pore formation in the lipid layer. In general, water diffusion into the microparticles is 
an important release rate controlling factor for the lipid coated beads. The osmotic 
activity of MAN should stipulate one of the osmotic driving force behind the water 
influx, which can be expected to hinder the diffusion of dissolved drug through the 
lipid layer in the opposite direction. Upon dissolution and diffusion would result in 
that pores form enabling exchange of dissolved molecules by release medium. Thus, 
MAN and drug concentration gradients form between inside and outside of the lipid 
layer, decreasing the barrier for drug diffusion and accelerating the release. 
Occasionally, the microparticle collapse along with MAN release also makes a 
contribution to drug release if the lipid layer is not thick enough to maintain the 
integrity of microparticles. Generally, the layer thickness is increased as the coating 
load of lipid increased, and determines the path-length for drug diffusion. Thus, thick 
lipid layer not only protects particles from degradation, but also lowers burst and 
release rate. Compared to MAN, MB exhibits much lower water solubility (800 g/mol, 
Swater = 1 g/L) [30] resulting in much lower burst and release rate.  
3.2. Methyl blue release from GS-coated microparticles  
   The wettability of the lipid is a key factor affecting the drug release properties of 
lipid matrices [8]. Higher wettability leads to faster drug release. In order to 
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investigate the effect of lipid type on the drug release profiles, the microparticles 
were coated with GS. GS is a mixture of 40–50% mono-, ~40% di- and ~5% 
triglycerides whereas HF is a mixture of 5% mono-, 29% di- and 66% triglycerides 
esters of fatty acids (C8-C18) [31, 32]. GS-based microparticles should take up more 
water due to GS's higher wettability, which may result in higher release rate. 
However, as shown in Fig. 4, comparable burst and release rates were observed for 
GS and HF-coated microparticles except that the microparticles containing 5 g and 
10 g GS showed higher burst release than HF coated particles.  
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Fig.4. MB (a) and MAN (b) release profiles of microparticles coated with different 
amounts of GS. 
   Lipids usually exhibit three polymorphic forms which are: disordered aliphatic 
chain conformation (α), intermediate packing (β
,
) and most dense packing (β) [33]. 
Changes in the polymorphic forms of lipid may influence the drug release 
behavior [34]. Fig .5 shows the DSC profiles of bulk lipid and lipid coated particles 
before and after release testing. Only one peak which commences from about 
40.1 °C could be seen for the bulk HF in the first heating cycle, which is designated 
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the most stable β-form. A decrease in the melting temperature of bulk HF is 
observed in the second heating cycle. After coating the β-polymorph could be 
identified. However, the HF-coated particles show signs of lower melting polymorphs 
(29.7 °C and 38.8 °C) after the release test. Thus HF partially transformed to the less 
stable form upon release testing. Since different polymorphic forms differ in their 
ability to include water and drug molecules in their lattice, the transition from the 
denser to looser packing form may accelerate drug release [35]. This may explain, 
why HF-coated microparticles showed comparable release profiles as GS-coated 
microparticles despite poor wettability of HF. The burst drug release is mainly caused 
by the breakage of more fragile particles at the beginning. In comparison with HF, 
GS-based particles took up more water in the first day and subsequently 
disintegration was more pronounced at the low coating levels of 5 g and 10 g. 
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Fig.5. DSC thermograms of HF (a), and GS (b). 
3.3. Effect of starting bead size on methyl blue release 
   Most parenteral suspensions have particle size and content limitations because of 
syringeability and injectability constraints [36, 37]. Hence, we prepared lipid-coated 
microparticles based on MAN core beads of 300 μm in diameter to examine the 
effect of starting bead size on MB release. Fig. 6 displays MB release profiles of 
lipid-coated microparticles produced with 300 μm and 500 μm carrier beads. A 
similar release duration was achieved for both starting beads when equivalent lipid 
amounts were used, irrespective of lipid type. Generally, the particles produced from 
300 μm MAN beads showed a trend to a slightly higher initial release which might be 
due to the different lipid layer thickness. Smaller carrier beads have a relatively 
higher specific surface area and thus a thinner coating results when the same 
absolute mass ratio of coating to core material is used [38]. The thicker lipid layer 
could protect the microparticles from breakage, decreasing the initial drug release. 
Additionally, larger microparticles with thicker lipid layer exhibit longer diffusion 
pathways. Water needs hence more time to penetrate into the system, which delays 
drug dissolution, pore creation and drug diffusion.  
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Fig.6. MB release profiles of HF (a) and GS (b) coated microparticles produced with 
500 and 300 μm carrier beads 
3.4. Aspartame release from lipid-coated microparticles 
    The aqueous solubility of the drug plays an important role in the formulation of 
coated particles when the mechanism of release is mainly by transport of the 
dissolved drug via diffusion through the film or through water-filled pores or 
channels within the coating [8]. Highly water-soluble drugs are generally released 
faster than poorly water-soluble compounds. To investigate the effect of the drug’s 
solubility on the release, different model drugs, MB and ASP were loaded on the 
300 μm MAN microparticles. These two model drugs of low molecular weights 
(MMB = 800 g/mol, MASP = 294 g/mol) differ significantly in water solubility 
(SMB = 1 g/L, SASP = 18.6 g/L) [30, 39]. Fig. 7 displays the release profiles of 
microparticles loaded with ASP and MB. As expected, particles containing ASP show 
higher burst and faster release than MB-loaded particles, irrespective of the type of 
lipid.  
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Fig.7. MB and ASP release profiles of HF (a) and GS (b) coated MAN microparticles 
   As the lipid-coated microparticles are exposed to aquous medium, the liquid 
penetrates into the microparticles, dissolves the drug to form a saturated solution (as 
long as undissolved drug is present), and then the drug diffuses out of the 
microparticles. So it is reasonable to expect a faster drug release from the 
microparticles loaded with a more soluble drug. Additionally drug solubility could 
facilitate the hydration process by permitting continuous penetration of water via 
diffusion and dissolution. Aqueous solubility also affects the osmotic pressure inside 
coated particles upon contact with the release medium, which impacts drug release. 
But in our case the osmotic pressure gradient should be unaffected by the drug as 
the MAN in the major constituent of all lipid coated beads. 
4. Conclusion 
   This study showed that the mini-Glatt fluid bed coater with a Wurster column 
could be utilized to form lipid-coated microparticles without agglomeration at 
modest temperature for sustained drug release by using organic solvent spray 
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coating. Microparticles with a thicker lipid coat were intact after release in contrast 
to particles with a thinner coating this thicker coating extended the release up to 25 
days for MB and 7 days for ASP. Drug release was driven by core bead dissolution 
and diffusion. HF-coated particles showed a comparable burst and release rate as 
GS-coated particles. The reduction in size of starting bead had only marginal effect 
on the drug release behavior. In contrast, the release of the more hydrophilic model 
compound was much faster than that of the less hydrophilic. Overall, these results 
provide an encouraging basis for lipid-coated microparticles for sustained release of 
sensitive biopharmaceutical drugs. 
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CHAPTER 4  
Lipid-coated polyol core microparticles 
for sustained release of protein 
Abstract 
   Parenteral sustained release systems for proteins which provide therapeutic 
levels over a longer period avoiding frequent administration, which preserve protein 
stability during manufacturing, storage and application and which are biodegradable 
and highly biocompatible in the body are intensively sought after. The aim of this 
study was to generate and study polyol core microparticles loaded with a monoclonal 
antibody IgG1 and coated with lipid either hard fat or glyceryl stearate at different 
coating levels. The protein was stabilized with 22.5 mg/mL sucrose, 0.1% PS 80, 
10 mM methionine in 10 mM His buffer pH 7.2 during the spray loading process. 30 g 
protein-loaded mannitol carrier microparticles were coated with 5 g, 10 g, 20 g and 
30 g of lipid, respectively. Placing more lipid onto the protein-loaded microparticles 
reduced both burst and release rate, and the particles maintained their geometric 
form during the release test. The IgG1 release from microparticles covered with a 
hard fat layer extended up to 6 weeks. The IgG1 was released in its monomeric form 
and maintained its secondary structure as shown by FTIR. Incomplete release of IgG1 
from glyceryl stearate-coated microparticles was observed, which may be due to the 
small pore sizes of the GS layer or a detrimental surfactant character of GS to protein. 
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Hence, these hard fat-coated polyol core microparticles have high potential for 
protein delivery. 
Keywords: Protein drug, Monoclonal antibody IgG1, Mannitol, Hard fat, Glyceryl 
stearate, Fluid bed coater, Microparticles, Sustained release, Stability, Lipids, Coating. 
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1. Introduction 
   Proteins play an important role in the treatment of severe diseases like cancer, 
autoimmune and inflammatory diseases for their high specificity, efficacy and low 
adverse effects [1]. Specifically, the successful applications of numerous therapeutic 
antibodies have resulted in an exponential growth in their research and development 
some of them showing blockbuster [2]. Owing to the inherent instability of protein 
drugs in the gastrointestinal tract, they are usually administered by parenteral 
administration [3, 4]. Many protein drugs exhibit short half-lives in vivo and multiple 
dosing schemes and frequent injections are necessary to achieve therapeutic drug 
levels, which result in poor patience compliance [5, 6]. Incorporation of proteins in a 
sustained release system for systemic delivery which can maintain therapeutic 
plasma levels for an extended period is of high interest [7, 8]. 
   Parenteral controlled release system delivering small molecular drugs and 
peptides are well established for decades. In contrast, their use for proteins is limited 
due to the protein sensitivity leading to instabilities during manufacturing, storage 
and application [5]. Lipids such as triglycerides have gained growing attention in this 
context due to their good biocompatibility and biodegradability [9, 10], which 
qualifies them to be an interesting alternative to polymeric matrix materials as they 
do not show the shortcomings of the commonly used PLA and PLGA polymers, such 
as the acidic microclimate and formation of detrimental polymer degradation 
products during erosion [11]. Lipid microparticles have been proposed as drug 
delivery systems for long-term release of peptide and protein drugs over days to 
months [12-14]. They are often prepared using organic solvent evaporation and melt 
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dispersion techniques by incorporating a protein solution in the molten/dissolved 
lipid dispersing the preemulsion in an aqueous phase [15]. The process technologies 
like spray-drying, extrusion, emulsion systems tested for controlled release protein 
drugs have shortcomings regarding protein stability, which resulting from high 
temperature or organic solvent use during the preparation process [16]. Additionally, 
incorporation of sufficient amounts of drug is troublesome due to the hydrophobic 
nature of the lipids [17]. 
   An organic solvent fluid bed spray coating technique was developed in Chapter 3 
for the lipid-coated polyol core microparticle preparation. This method featured the 
advantage of a microparticle production process at moderate temperature which 
could secure the stability of the protein drug during manufacturing. The model 
compounds methyl blue and aspartame were released upon dissolution of the polyol 
core beads over 25 and 7 days, respectively. Furthermore, we previously established 
successful loading of polyol and sugar beads with protein drugs in a fluid bed 
system [18] and this renders lipid-coated polyol core microparticles very interesting 
for sustained release application of protein drugs. Consequently, we intended to 
develop a new process to load an IgG1 antibody model onto polyol beads and 
provide them with a release controlling lipid layer in a mini fluid bed system. Protein 
stability during fabrication and release as well as the duration of release were the 
main critical parameters of interest. In order to prevent IgG1 unfolding at the 
air-liquid interface and subsequent aggregation, surfactant was added as stabilizing 
excipients during spray loading. Turbidity analysis, light obscuration measurement 
and size-exclusion chromatography (SEC) analysis were carried to evaluate aggregate 
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formation upon manufacturing and release. Additionally, the secondary structure of 
incorporated IgG1 was analyzed by Fourier transform infrared (FTIR) spectroscopy. 
2. Materials and Methods 
2.1. Materials 
   Pearlitol® 500DC-Mannitol (MAN) was kindly provided by Roquette Corporate, 
Darmstadt, Germany. A 20.9 mg/mL IgG1 monoclonal antibody solution in 10 mM 
histidine pH 7.2 was used. Sucrose, polysorbate 80 (PS 80) and L-Methionine were 
purchased from Sigma-Aldrich, Munich, Germany. Witepsol® E85 (hydrogenated 
coco-glycerides, HF) and Imwitor® 900 (glyceryl stearate with a monoester content of 
40-55%, GS) were kindly provided by Sasol GmbH, Hamburg, Germany. Isopropanol 
(99.7%) was supplied by the reagent center of the University of Munich, Germany.  
2.2. Methods 
2.2.1. Optimization of formulation for IgG1 loading 
   Sucrose was dissolved in 10 mL his buffer (pH 7.2, 10 mM) containing 10 mM 
methionine and 0.02% PS 80 to final concentrations of 22.5 mg/mL, 45 mg/mL or 
90 mg/mL. 30 g MAN particles were loaded with the former solutions in a Mini-Glatt 
fluid bed system with Wurster insert (Glatt GmbH, Binzen, Germany). The detained 
operation conditions were Tinlet: 35 °C; pprocess: 1.0 bar; patomizing air: 1.0 bar; spray rate: 
1.0 mL/min; and spray nozzle diameter: 0.3 mm. Based on the optimal sucrose 
concentration, PS 80 concentration was increased to 0.1% to prevent IgG1 
aggregation under the same condition. 
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2.2.2. Preparation of drug-loaded starting cores 
   The spray solution (10 mL) containing 3.1 mg/mL IgG1, 0.1% PS 80, 22.5 mg/g 
sucrose, and 10 mM methionine in 10 mM histidine buffer pH 7.2 was filtrated 
through an Acrodisc 0.2 µm PES syringe filter. Mannitol particles (30 g) were loaded 
with the drug solution in a Mini-Glatt fluid bed system with Wurster insert (Glatt 
GmbH, Binzen, Germany). The detailed operation conditions were Tinlet: 35 °C; 
pprocess: 1.0 bar; patomizing air: 1.0 bar; spray rate: 1.0 mL/min; and spray nozzle 
diameter: 0.3 mm. After loading, the particles were dried for additional 15 min at 
35 °C in the fluid bed. The drug loaded particles were collected and kept at 2-8 °C 
until lipid coating. 
2.2.3. Preparation of lipid-coated microparticles 
   Lipid was dissolved at 2% w/v in isopropanol at 70 °C. 30 g drug-loaded 
microparticles were coated with the lipid solution in the Mini-Glatt fluid bed with 
Wurst insert at, Tinlet: 40 °C for GS and 30 °C for HF; pprocess: 0.7 bar; patomizing air: 0.5 bar; 
spray rate: 7.0 mL/min; and spray nozzle diameter: 0.5 mm. After coating, the 
microparticles were annealed for additional 15 min at the same conditions. 
2.2.4. High performance size exclusion chromatography (HP-SEC) 
   HP-SEC was performed on an Agilent 1100 series HPLC system (Agilent 
Technologies, Germany). The autosampler and the column were controlled at 20 °C 
and 23 °C, respectively. The samples were centrifuged for 5 minutes at 2000 rpm. For 
each sample solution, 250 µl supernatant was injected onto a Tosoh TSKgel® 
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G3000SWXL column (7.8x300 mm) (Tosoh Bioscience, Stuttgart, Germany) using a 
mobile phase of 100 mM sodium phosphate buffer with additional 100 mM sodium 
sulfate pH 6.8 at a flow rate of 0.5 ml/min. UV detection at 280 nm was used. The 
chromatograms were analyzed regarding retention times and area under the curve 
(AUC) with ChemStation® B.02.01-SR2 (Agilent Technologies). 
2.2.5. Determination of drug loading of lipid-coated microparticles 
   1.0 g of HF-coated particles was dispersed in 10 ml PBS buffer at 45 °C. After 
cooling down to room temperature, approximate 2 mL slurry were filtered through a 
0.2 μm filter to remove the lipid after. Filtrate was analyzed for drug content by 
HP-SEC. Each experiment was performed in triplicate.  
2.2.6. Microparticle morphology 
   The morphology of microparticles was analyzed by use of a light optical 
microscope (Olympus BX50 F4, Olympus, Tokyo, Japan) equipped with a digital 
camera (HVC 20, Hitachi, Maidenhead, GB).  
2.2.7. Turbidity 
   The turbidity of IgG1 solution in formazine nephelometric units (FNU) was 
determined with a NEPHLA turbidimeter (Dr. Lange, Düsseldorf, Germany), based on 
light scattering in a 90 ° angle at λ = 860 nm. The system was calibrated with a 
formazine standard. 1000 mg of microparticles was dissolved in 6 ml PBS buffer 
(10 mM, pH 7.4, 2.7 mM KCl, 137 mM NaCl, 0.05% NaN3). Approximately 2 mL of 
each sample were used for analysis in triplicate. 
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2.2.8. Light obscuration 
   Light obscuration tests were carried out according to Ph.Eur. 2.9.19. The particle 
counting of subvisible particles in a size range between 1 and 200 µm was conducted 
using a SVSS-C instrument and associated analysis software (PAMAS GmbH, 
Rutesheim, Germany). For each sample (n = 3), three measurements of a volume of 
0.3 mL with a pre-run volume of 0.3 mL at fixed fill rate, emptying rate and rinse rate 
of 5 mL/min were performed. Prior to each measurement the system was rinsed with 
high purified water until particle counts of less than 30 particles/mL were 
determined. The obtained results represented the mean value of the particle counts 
of three measurements, referred to a sample volume of 1.0 mL. 
2.2.9. In vitro release 
   Protein release was studied in PBS pH=7.4 on a horizontal shaking incubator at 
37 °C (60 rpm). Approximately 1.0 g of drug-loaded particles were suspended in 3 mL 
buffer, transferred into a dialysis bag with 1 MDa cutoff and immersed into a 15 mL 
disposable plastic tube with 7 mL of PBS release medium containing 0.01% NaN3. At 
designated time points, 350 µl release medium were withdrawn from the tube and 
replaced with the same amount of fresh release medium. The drug content in the 
release medium was quantified using a HP-SEC. Each experiment was performed in 
triplicate. 
2.2.10. Fourier-transformed-infrared spectroscopy (FTIR) 
   The release medium was analyzed using a Bruker Tensor 27 FTIR spectrometer 
CHAPTER 4 PROTEIN RELEASE FROM LIPID COATED MICROPARTICLES  
50 
 
(Ettlingen, Germany) equipped with a Bio ATR measuring cell and an MCT detector at 
25 °C. 35 µL of the sample was spread under dry nitrogen to ensure an equal 
distribution on the crystal surface and analyzed against PBS buffer as blank. For each 
experiment, 100 scans were set for the blank and sample with a resolution of 4 cm-1 
and water vapor correction. The data were analyzed with the OPUS 6.5 software for 
second derivative spectra and vector normalization. 
3. Results and discussion 
3.1. Optimization of formulation for IgG1 loading 
   Generally, temperature, air-liquid interfaces and dehydration are three main 
stress factors affecting the chemical and physical protein instabilities during spray 
drying [19]. As the inlet air temperature is lower in the fluid bed system, thermal 
denaturation during drug loading could be regarded as negligible. However, the 
tremendous expansion of the air-liquid interface may lead the orientation of 
hydrophobic amino acid residues towards the nonaqueous environment and 
subsequent protein unfolding and aggregation [19-21]. Meanwhile, the protein 
molecules are deprived of the surrounding and protective water, and are 
thermodynamically destabilized by losing their hydrogen bonding to water 
molecules [19]. 
   Addition of surfactant e.g. polysorbates (PS) and other excipients e.g. polyols, 
sugars, salts and amino acids are effective in protecting the stability of a protein drug 
during spray drying [19, 20, 22, 23]. Surfactants adsorb at the air-liquid interface 
reducing the appearance of protein molecules at the surface [19, 20]. Small molecule 
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excipients could be incorporated as "water substitutes" replacing the hydrogen 
bonding existing in an aqueous environment [19, 23]. Therefore, PS 80 and sucrose 
were selected as two stabilizers for the drug loading in the fluid bed coater. Although 
improved protein stabilization has been shown with increasing concentration of 
sucrose, its addition is limited by the formation of more viscous solutions result in 
microparticle agglomeration in the fluid bed. Thus, the concentrations of PS 80 and 
sucrose have to be optimized during the IgG1 loading process. As shown in the Fig.1, 
protein loading with a formulation containing 22.5 mg/mL sucrose did not show 
agglomeration, whereas large agglomerates were observed at higher sucrose 
concentrations. 
  
  
Fig. 1. Visual appearance of mannitol beads after loading with placebo, containing 
before loading 22.5 mg/mL 
45 mg/mL 90 mg/mL 
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22.5, 45 or 90 mg/mL sucrose. 
   The influence of PS 80 concentration on IgG1 stability after drug loading was 
analyzed via visual inspection, turbidity, light obscuration and HP-SEC. At a level of 
0.1% PS 80 in the spray solution, the redissolved IgG1 loaded microparticles did not 
show any sign of aggregation, neither visually (Fig.2) nor in turbidity and subvisible 
particle concentration compared to placebo samples (Fig.3) nor in HP-SEC with 100% 
monomer recovery. In contrast, at 0.02% PS 80 slight formation of particles (Fig.2, 
Fig.3) and 0.4% dimers in HP-SEC were found. According to these results, it was 
concluded that 22.5 mg/mL sucrose, 0.1% PS 80 in 10 mM His buffer pH 7.2 
presented a suitable formulation for IgG1 loading. 
 
 
0.02% PS 
0.1% PS 
Placebo IgG loaded 
Placebo IgG loaded 
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Fig. 2. Visual appearance of reconstitutions of placebo and IgG1 loaded 
microparticles from a formulation composed of 0.02% or 0.1% PS 80, 22.5 mg/g 
sucrose, and 10 mM methionine in 10 mL histidine buffer (pH 7.2, 10 mM), 1 g of 
microparticles were redissolved in 6 ml PBS buffer (10 mM, pH 7.4, 0.05% NaN3). 
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Fig. 3. Results of light obscuration and turbidity of reconstitutions of placebo and 
IgG1 loaded microparticles from a formulation composed of 0.02% or 0.1% PS 80, 
22.5 mg/g sucrose, and 10 mM methionine in 10 mL histidine buffer (pH 7.2, 10 mM), 
1 g of microparticles were redissolved in 6 ml PBS buffer (10 mM, pH 7.4, 0.05% 
NaN3). 
3.2. IgG1 release from lipid-coated microparticles 
   The obtained in vitro release profiles of IgG1 from lipid coated microparticles are 
illustrated in Fig. 4. IgG1 loaded microparticles coated with 5 g HF exhibited an 
approximate 50% burst release and subsequently nearly complete release (81.9% 
(SD=16.8%, n=3)) within two weeks. Coating with 10 g lipid reduced the protein 
release rate. This deceleration of the release became more apparent with the 
addition of more lipid. For the microparticles coated with 20 g and 30 g lipid, IgG1 
was released in a sustained manner over 5 weeks and 6 weeks without initial burst 
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release. For methyl blue the release period was only extended to 14 and 25 days for 
20 and 30 g lipid coat and much shorter for 5 and 10 g (Chapter 3). In parallel to this 
prolongation of the release period, the total amount of drug released differed with 
the size of drug. Complete release was determined for methyl blue, whereas about 
25% of IgG1 antibody remained in the microparticles coated with 20 or 30 g lipid. 
Compared to HF, GS exhibits a higher wettability and more stable polymorphic 
structure (Chapter 3). Fig.4b depicts IgG1 release profiles of microparticles coated 
with different amount of GS. A long term sustained release of IgG1 was not observed 
at any GS coating level. After a burst release within the first day, only little amounts 
of IgG1 were released in the following days. 
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Fig.4. IgG1 release profiles of microparticles coated with different amounts of HF (a) 
or GS (b), 5 g:■; 10 g:●; 20 g:▲; 30 g:▼. 
   Almost all of the protein-loaded microparticles coated with 5 g HF were degraded 
after the release test period whereas this was the case for only a small amount of 
microparticles coated with more lipid (Fig. 5). Thus, particle degradation substantially 
contributes to the drug burst and release of 5 g lipid-coated microparticles. Drug 
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release from microparticles with a thicker lipid layer, which maintained their 
geometric form during the release test, was more controlled by Fickian diffusion. 
Therefore, the microparticles coated with 5 g lipid showed similar release for methyl 
blue and IgG1. The slower IgG1 release from microparticles with more lipid could be 
explained by the increase in drug size resulting in a lower diffusion coefficient [24] 
and limited movement if the sizes of pores resulting from dissolution of the polyol 
core beads were too small for free diffusion of large molecule 
IgG1 (150 kDa, hydrodynamic diameter ≈ 11 nm) [25]. Additionally, a small pore size 
can explain the partial IgG1 entrapment by the lipid matrix leading to incomplete 
release. The small pores formed by MAN dissolution and diffusion in GS coated 
microparticles may be too small for the release of large IgG1 molecules in contrast to 
methyl blue and aspartame. The incomplete release of protein may also be related to 
the surfactant characters of GS, which may cause the protein denaturation. 
Consequently, the IgG1 stability after release was analyzed in the following.                 
         before release                        after release 
   
(a1) (a2) 
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Fig.5. Microscope images of mannitol particles coated with 5g (a), 10g (b), 20g (c) 
and 30g (d) HF before (left) and after (right) release 
3.3. IgG1 stability 
   The HP-SEC analysis revealed that IgG1 was totally released as monomer over the 
entire release period without formation of fragments, dimers or higher molecular 
(b1) (b2) 
(c1) (c2) 
(d1) (d2) 
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weight species. In addition, to determine if the fabrication process and the long term 
release period induced conformational changes of the IgG1, analysis of the 
secondary structure was performed by FTIR. Several transmittance bands (e.g., 
amide I, amide II and amide III) could be used for structure analysis of IgG1 [26, 27]. 
The IgG1 exhibits major absorption peaks at 1612 cm-1, 1640 cm-1, 1690 cm-1, which 
correspond to the native β-sheet structure [28, 29]. So Fig.7 shows the second 
derivative spectrums of amide I and amide II bands measured in transmission 
obtained for IgG1 before and after release. For the HF-coated microparticles after 
release, the second derivatives of the amide I and II spectra showed no significant 
difference compared to native IgG1. It can be concluded that the loading and the 
lipid coating process as well as the IgG1 release from HF-coated microparticles did 
not induce relevant changes in secondary structure. However, for the GS-coated 
microparticles, formation of a new band at 1633 cm-1 was observed. Typically, upon 
denaturation monoclonal antibodies form anti-parallel β-sheet giving rise to a peak 
near 1620 cm-1 [30]. This change in FTIR spectrum may indicate a structure change of 
the IgG1 in cause of the release test and could explain the incomplete release from 
GS-coated microparticles. 
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Fig.6. FTIR second derivative spectra of IgG1 after 92 days release from HF (a) and 
GS-coated (b) particles 
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4. Conclusion 
   In this work, mannitol microparticles were loaded with IgG1 and coated with lipid 
in a fluid bed system to control the sustained release of the protein. 22.5 mg/mL 
sucrose, 0.1% PS 80, 10 mM methionine in 10 mM His buffer pH 7.2 presented a 
suitable formulation for IgG1 loading process. An extended release manner over 
6 weeks could be achieved by coating 30 g HF. It was shown that IgG1 was totally 
released as monomer. Furthermore, the particle fabrication procedure and the long 
release periods did not affect the secondary structures of IgG1 from HF-coated 
microparticles. Sustained release of IgG1 was not observed from GS-coated 
microparticles, which may result from the small pore sizes of GS layer or detrimental 
surfactant character of GS. Thus, HF-coated microparticles developed in this study 
could be a promising protein delivery systems. 
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CHAPTER 5  
Spray drying of silica microparticles for 
sustained release application with a new 
sol-gel precursor 
Abstract 
   A new precursor, tetrakis(2-methoxyethyl) orthosilicate (TMEOS) was used to 
fabricate microparticles for sustained release application, specifically for 
biopharmaceuticals, by spray drying. The advantages of TMEOS over the currently 
applied precursors are its water solubility and hydrolysis at moderate pH without the 
need of organic solvents or catalyzers. Thus a detrimental effect on biomolecular 
drug is avoided. By generating spray-dried silica particles encapsulating the high 
molecular weight model compound FITC-dextran 150 via the nano spray dryer 
Buchi-90, we demonstrated how formulation parameters affect and enable control 
of drug release properties. The implemented strategies to regulate release included 
incorporating different quantities of dextrans with varying molecular weight as well 
as adjusting the pH of the precursor solution to modify the internal microstructures. 
The addition of dextran significantly altered the released amount, while the release 
became faster with increasing dextran molecular weight. A sustained release over 
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35 days could be achieved with addition of 60 kD dextran. The rate of 
FITC-Dextran 150 release from the dextran 60 containing particles decreased with 
higher precursor solution pH. In conclusion, the new precursor TMEOS presents a 
promising alternative sol-gel technology based carrier material for sustained release 
application of high molecular weight biopharmaceutical drugs. 
Keywords: TMEOS, Sol-gel, Spray drying, Dextran, Microparticles, Sustained release 
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1. Introduction 
   The sol-gel technology is presently believed to be one of the most promising 
approaches for controlled drug release [1-4]. Its main advantage lies in the fact that 
the entrapment of drugs in a porous network proceeds without formation of 
covalent linkages between drug molecules and matrix [1]. As a result, the drug 
payload is intact, which is specifically important for biomolecular drugs like proteins 
[5-10]. Additionally, entrapment in a nanostructured amorphous glass matrix can 
support the long-term and thermal stability of proteins [1, 9-11].  
   The sol-gel processing includes the use of a precursor, often metal or silicon 
alkoxides. When an alkoxide is mixed with water, it experiences hydrolysis and the 
products are involved in condensation reactions leading first to a sol formation 
followed by cross-linking of sol particles which causes the sol-gel transition and 
consequently porous network formation [12, 13]. The silica sol-gel process is strongly 
influenced by additives such as short-chain alcohols [14], electrolytes [15], and 
hydrophobic solubilizates [16]. Silica as a carrier matrix exhibits several advantages 
over metal alkoxides, as it is relatively cheap and easy to purify, with excellent 
physical and chemical stability, good biocompatibility, and biodegradability with 
favorable tissue responses in vitro and in vivo [17-19]. Thus, silica-based sol-gel 
materials are frequently used for drug delivery purpose [1].  
   Although sol-gel silica materials have many advantages for controlled drug 
release application, there still exist some disadvantages. Conventional silica 
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precursors such as tetramethoxysilane (TMOS) and tetraethoxysilane (TEOS) are 
insoluble in water. In order to achieve a uniform sol, an organic solvent or surfactant 
is added and extreme conditions of pH and high temperature are required, which are 
unfavorable for the encapsulation of biomolecular drugs [20]. Furthermore, in the 
course of the reaction process, short-chain alcohols such as methanol or ethanol as 
by-products of the hydrolysis of tetraalkyl orthosilicates are generated, which 
negatively impact biomolecule resulting in unfolding and aggregation and 
subsequently restricts their use [21]. In contrast, tetra(2-hydroxyethyl) orthosilicate 
(THEOS) has been investigated to address the solubility, temperature and pH 
problems associated with TEOS and TMOS [22]. Moreover, it is known that 
ethyleneglycol which is produced during THEOS hydrolysis has little effect on 
surfactant self-assemblies and phase behavior compared to methanol or ethanol 
[20-25]. However, THEOS alone does not cause the jellification of water at ambient 
conditions over a period of a month. Additives such as such as polysaccharides are 
necessary to trigger the sol-gel processes [25].  
   Those problems may be circumvented by changing the ethoxy, methoxy or 
ethylene glycoxy groups of the precursor against ethylene glycol 
monomethylether (EGMM). EGMM with boiling point 124.5 °C is readily removed 
accompanying the water evaporation. As we found, this new precursor tetrakis 
(2-methoxyethyl) orthosilicate (TMEOS) is water soluble and the time of water 
jellification can be controlled from a few minutes to a few hours by adjusting the pH 
value between pH 6.0 to 8.0 without the need for additives at room temperature. 
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Furthermore, hydrolysis renders longer chain alcohol which can be expected to show 
better compatibility with sensitive protein drugs. In the present study, the 
compatibility of ethylene glycol monomethylether (EGMM) as a by-product produced 
in course of TMEOS hydrolysis was checked with sensitive IgG1 antibody. Then the 
effects of pH and ionic strength on TMEOS gelation were examined. A nano spray 
dryer Buchi-90 was used to produce silica gel microparticles for release application. 
Prior to protein drug loading, FITC-dextran 150 (FITC-Dx 150) was used as a high 
molecular weight model compound to regulate the drug release kinetics.dextrans of 
different molecular weight were incorporated into the silica microparticles. 
Additionally, the effect of several parameters such as silica/additive ratio, molecular 
weight of additives and pH of precursor solution were addressed. 
2. Materials and Methods 
2.1. Materials 
   Tetrakis (methoxyethoxy) silane (TMEOS) was purchased from Suzhou Chum-Win 
New Material Science & Technology Co,. Ltd., Suzhou, China, Fluorescein 
isothiocyanate dextran 150 kDa (FITC:Glucose = 1:160)  (FITC-Dx 150) was 
purchased from Sigma-Aldrich, Munich, Germany and Dextran 1 (Dx 1), Dextran 5 
(Dx 5) and Dextran 60 (Dx 60) were purchased from Pharmacosmos A/S, Holbaek, 
Denmark. A 2 mg/mL IgG1 monoclonal antibody in 10 mM PBS pH 7.2 was used. 
Ethylene glycol monomethylether (EGMM, 99.5%) was supplied by the reagent 
center of the University of Munich, Germany. All other reagents used were of 
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analytical grade. Deionized water (Milli-Q) was used for all precursor preparation. 
2.2. Methods 
2.2.1. Turbidity 
   The turbidity of IgG1/EGMM mixtures in formazine nephelometric units (FNU) 
was determined with a NEPHLA turbidimeter (Dr. Lange, Düsseldorf, Germany), 
based on light scattering in an 90 ° angle at λ = 860 nm. The system was calibrated 
with a formazine standard. Approximate 2 mL of each sample were used for analysis. 
2.2.2. Light obscuration 
   Light obscuration tests were carried out according to Ph.Eur. 2.9.19. The particle 
counting of subvisible particles in a size range between 1 and 200 µm was conducted 
using a SVSS-C instrument and associated analysis software (PAMAS GmbH, 
Rutesheim, Germany). For each sample (n = 3) three measurements of a volume of 
0.3 mL with a pre-run volume of 0.3 mL at fixed fill rate, emptying rate and rinse rate 
of 5 mL/min were performed. Prior to each measurement the system was rinsed with 
high purified water until particle counts of less than 30 particles/mL were 
determined. The obtained results represented the mean value of the particle counts 
of three measurements, referred to a sample volume of 1.0 mL. 
2.2.3. High performance size exclusion chromatography (HP-SEC) 
   HP-SEC was performed on an Agilent 1100 series HPLC system (Agilent 
Technologies, Santa Clara, California, USA). The autosampler and the column were 
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temperature controlled at 20 °C and 23 °C, respectively. The samples were 
centrifuged for 5 minutes at 2000 rpm. For each sample solution, 40 µl supernatant 
were injected onto a Tosoh TSKgel® G3000SWXL column (7.8x300 mm) (Tosoh 
Bioscience, Stuttgart, Germany) using a mobile phase of 100 mM sodium phosphate 
buffer with additional 100 mM sodium sulfate pH 6.8 at a flow rate of 0.5 ml/min. 
The eluted sample was detected by UV absorption at 280 nm. The chromatograms 
were analyzed regarding retention times and the area under the curve (AUC) with 
ChemStation® B.02.01-SR2 (Agilent Technologies). 
2.2.4. Particle preparation 
   To investigate the effects of additives, different formulations were prepared 
(Table 1). The total mass content of excipients was set to 5.5% (w/v). In a typical 
procedure, FITC-Dx 150 solution in 10 mM PBS was mixed with TMEOS to a final 
concentration of 0.05%. Hydrolysis was performed for 2 hours. The spray drying 
conditions in the nano spray dryer Buchi-90 were Tin/Tout: 120 °C /58 °C, flow rate of 
drying air: 120 L/min, atomizing mesh size: 7.0 μm. Spray solutions were filtered 
through a0.2 μm PVDF syringe filter prior to spray drying. 
Table 1: Formulations of precursors for spray drying 
Run number 
Silica 
dioxide 
(%w/v) 
Dextran (%w/v) 
Sucrose (%w/v) 
pH 
1 kDa 5 kDa 60 kDa 
1 5.5 0.00 0.00 0.00 6.0 
2 5.0 0.5 0.00 0.00 6.0 
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3 4.5 1.0 0.00 0.00 6.0 
4 3.7 1.8 0.00 0.00 6.0 
5 1.8 3.7 0.00 0.00 6.0 
6 5.0 0.00 0.5 0.00 6.0 
7 4.5 0.00 1.0 0.00 6.0 
8 3.7 0.00 1.8 0.00 6.0 
9 1.8 0.00 3.7 0.00 6.0 
10 5.0 0.00 0.00 0.5 6.0 
11 4.5 0.00 0.00 1.0 6.0 
12 3.7 0.00 0.00 1.8 6.0 
13 1.8 0.00 0.00 3.7 6.0 
14 
 
4.5 0.00 0.00 1.0 6.2 
15 4.5 0.00 0.00 1.0 6.4 
2.2.5. Particle morphology and size  
   The particles were visualized with scanning electron microscopy (SEM) using a 
Jeol JSM-6500F instrument (Jeol Ltd., Tokyo, Japan) with Inca Software (Oxford 
instruments, Oxfordshire, UK) at an accelerating voltage of 2.0 kV. They were 
sputtered with carbon. SEM images were further analyzed for particle size by using 
the integrated software in a Keyence VHX-500FD digital microscope (Keyence, 
Neu-Isenburg, Germany). Approximately 100 particles were analyzed for each 
sample. 
2.2.6. In vitro release 
   FITC-Dx 150 release was studied in PBS buffer (0.01 M phosphate; 0.138 M NaCl; 
0.027 M KCl, pH 7.4) at 39 °C using a shaking incubator (60 rpm). Approximately 
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100 mg of drug-loaded particles and 1 mL buffer were placed in a 1 MDa cutoff 
dialysis bag and immersed into a 15 mL disposable plastic tube with 4 mL PBS 
containing 0.05 % NaN3. At designated time points, 200 μL of release medium were 
withdrawn and replaced with the same amount of fresh release medium. 
FITC-Dx 150 was quantified by fluorescence measurement (Varian Cary Eclipse, now 
Agilent Technologies, Santa Clara, California, USA; ex. 492 nm; em. 518 nm) in 
96-well plates.  
3. Results and discussion 
3.1. Compatibility of EGMM with IgG1 
   Hydrolysis of TMEOS generates ethylene glycol monomethylether (EGMM) which 
can evaporate in the course of the spray-drying process. One of the major 
requirements in formulation development is the compatibility of the by-product with 
the incorporated drug. Accordingly, the compatibility was exemplarily tested with an 
IgG1 antibody. The compatibility of different EGMM concentrations with IgG1 was 
assessed via visual inspection, turbidity, light obscuration and HP-SEC measurement. 
These analytical methods were used to identify any aggregation or fragmentation 
phenomena of IgG1. All IgG1 samples showed visaul turbidity compared to the 
placebo samples. This was consistent with the turbidity measurement and light 
obscuration. These results indicated interactions between EMGG and IgG1 leading to 
formation of layer IgG1 aggregates. However, no soluble aggregate or fragment 
formation of IgG1 samples was observed by HP-SEC analysis with nearly 100% 
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monomer recovery except for the sample containing 50% EGMM. Based on these 
results, it was concluded that at the low EGMM concentrations arising in the 
particles during gel formation are compatible with IgG1. Therefore, the maximal 
TMEOS concentration of spray solution was set to 30% (equals to 5.5% silica dioxide), 
which would yield a safe EGMM concentration of 6.95% for proteins upon hydrolysis. 
In future studies additional purity analysis of TMEOS will be performed and the 
impact of protein stabilizing excipients like sugars and surfactants will be tested. 
 
 
Figure 1. Visual appearance of mixtures of IgG1 (A) or placebo (B) solutions with 
different EGMM concentration, a 2 mg/mL IgG1 in 10 mM PBS pH 7.2 was used. 
 
(A) 
(B) 
50% EGMM 30% EGMM 15% EGMM 10% EGMM 8% EGMM 0% EGMM 100% EGMM 
50% EGMM 30% EGMM 15% EGMM 10% EGMM 8% EGMM 0% EGMM 100% EGMM 
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Table 2: Analysis of mixtures of IgG1 or placebo solutions with different EGMM 
concentration by turbidity, particle counter SVSS-C and HP-SEC, a 2 mg/mL IgG1 in 10 
mM PBS pH 7.2 was used. 
Composition Turbidity 
≥1μm Particle 
concentration (/mL) 
Monomer recovery 
IgG1 1.87 9409  
EGMM 0.6 3646  
PBS 0.65 61  
50% EGMM 7.34 10105 0.6% 
30% EGMM 17.6 141308 98.2% 
15% EGMM 13.76 210226 101.3% 
10% EGMM 11.15 162903 100.9% 
8% EGMM 9.35 144954 101.0% 
Placebo 50% EGMM 2.29 27300  
Placebo 30% EGMM 4.21 75232  
Placebo 15% EGMM 4.05 39533  
Placebo 10% EGMM 3.56 8396  
Placebo 8% EGMM 3.25 3429  
3.2. Effects of pH and ionic strength on TMEOS gelation 
   Upon spray drying, a pre-hydrolyzed sol-gel solution is atomized into a heated 
reactor to yield porous particles. It is important to clarify the time tgel required for 
gelation of the sol to avoid nozzle blockage. Ionic strength and pH are two important 
parameters impacting the hydrolysis and condensation of silica precursor [12]. The 
dependency of tgel and these two parameters was studied. For protein drug, the 
formulation should be at moderate pH. Here, four different concentrations of PBS 
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were used to investigate the effect of ionic strength on the gelation time between 
pH 6.0 to pH 8.0. Formation of EGMM during the sol-gel transition could be 
confirmed is characteristic odour. As shown in Fig.2, tgel decreased with higher pH 
and PBS concentration. The time of water jellification can be controlled from a few 
minutes to a few hours by adjusting pH and PBS concentration without the need for 
additives.  
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Figure 2. Effects of pH and ionic strength on TMEOS gelation time, 0.6 mL TMEOS 
was mixed with 1.4 mL four different concentrations (■:10 mM, □:30 mM, 
●:50 mM and ○:200 mM) of PBS between pH 6.0 to pH 8.0.  
3.3. Particle morphology 
   Mesh size and formulation parameters like total solid content are predominant 
parameters affecting the size and morphology of particles spray dried in the Buchi-90 
nano [26]. The particles of all the 15 runs showed similar size of 2 μm as they were 
fabricated with the same mesh size for equivalent total solid content. The absence of 
the characteristic EGMM odour for the silica particle as powder as well as suspended 
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in PBS buffer confirmed the EGMM evaporation upon spray-drying. But the 
microparticles were observed to exhibit different morphologies depending on the 
composition of the precursor solution (Fig. 3). Microparticles spray dried with low 
sugar content were of spherical shape with smooth outer surface. The incorporation 
of more sugar 1.8% Si/3.7% Dx induced deformations.  
   
 
 
 
 
Figure.3. SEM photographs of spray-dried particles with different silica/Dx 5 ratios at 
pH 6.0, (A) 5.5%:0.0%, (B) 5.0%:0.5%, (C) 4.5%:1.0%, (D) 3.7%:1.8%, (E) 1.8%:3.7%. 
   The particle formation process during spray drying can be described by solvent 
evaporation and diffusion of solutes in the droplet because of heat and mass transfer 
[27, 28]. At the beginning, a moisture-rich droplet shrinks isotropically while the 
water is evaporated. As the droplet keeps shrinking, a shell is gradually formed on 
the surface. With continuing evaporation, moisture from inside the droplet exerts 
compressive capillary stress on the shell, which could induce surface deformation. 
The formulation composition determines the shell properties, which, in turn, govern 
(A) (B) (C) 
(D) (E) 
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the observed particle morphology. The solubility of the formulation components is 
probably the most important factor that influences the spray dried particle 
formation [29]. At the earlier stage of solvent evaporation, the less water-soluble 
components precipitate, leading to the formation of a solid shell that eventually 
collapses as drying continues, resulting in corrugated particles [30]. In contrast, 
highly soluble components, precipitation is expected to appear later in the 
evaporation process and relatively homogeneously throughout the droplet, resulting 
in a smooth, spherical particle. Formulation components such as mannitol will tend 
to crystallize, in spite of its high aqueous solubility, whereas sugars, such as sucrose, 
raffinose, trehalose, lactose, will tend to precipitate as an amorphous solid, resulting 
in irregular particle formation [31]. Here, the morphology of particles with relatively 
low sugar content (1.8 wt% Dx) results from the typical regime with solute. The 
addition of 3.7% Dx induced a wrinkled morphology. The high Dx concentration led 
to a high surface viscosity with subsequent early precipitation and shell formation 
that resisted isotropical shrinkage with further drying.  
3.4. Effect of silica/Dx ratio on release rate 
   The release profiles of FITC-Dx 150 from the spray-dried microparticles with 
different silica/Dx1 ratios are shown in Fig.4 (A). Pure silica microparticles showed a 
very slow release with a cumulative release of only around 8% after 4 weeks. 
Incorporation of Dx 1 enhanced the release. Around 20% of FITC-Dx 150 was released 
within 2 days for microparticles with the addition of Dx 1 at levels from 0.5% to 1.8%, 
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while 60% was released in the same period with increasing the amount of Dx 1 to 
3.7%. This acceleration of the release became more apparent with the addition of 
Dx 5 and Dx 60. Within 4 days, up to 25%, 30%, 50%, and 100% of FITC-Dx 150 were 
released from the microparticles containing 0.5%, 1.0%, 1.8% and 3.7% 
Dx 5 (Fig.4 (B)). Furthermore, sustained release over 35 days and 21 days were 
achieved by incorporating 1.0% and 1.8% Dx 60, respectively (Fig.4 (C)). Generally, 
increase of Dx molecular weight accelerated the release when the equivalent 
amount of Dx was added. Since the microparticles showed relatively similar size and 
morphology with nearly spherical shape and smooth surface except at a silica/Dx 
ratio of 3.7%/1.8%, the difference in the release behavior could be attributed to the 
addition of Dx to the matrix.  
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Figure.4. Release profiles of FITC-Dx150 from microparticles of different silica/Dx1(A), 
Dx5(B) and Dx60(C) ratio prepared at pH 6.0, 5.5%Silica/0.0%Dx: ■ ; 
5.0%Silica/1.0%Dx: □ ; 4.5%Silica/1.0%Dx: ● ; 3.7%Silica/1.8%Dx: ○ ; 
1.8%Silica/3.7%Dx:▲. 
   Generally, the silica particles can be considered as matrix systems in which the 
drug is uniformly distributed within the gel matrix. Liberation of the drug occurs 
through penetration of solvent into the pores, cracks and interparticular spaces of 
the matrix. The drug slowly dissolves in the permeating fluid phase and diffuses from 
the system along the solvent-filled capillary channels [32]. The release from the silica 
matrix is governed by diffusion and simultaneous matrix degradation [33]. 
Incorporated of Dxs increased the release due to their high hydrophilicity and water 
solubility. Dissolution of Dx upon contact with the release medium increases the 
inner mesopore size of the microparticles and provides more channels for drug 
diffusion, inducing drug molecules to be released. This is consistent with the particle 
morphology after release (Fig.5). In the absence of Dx, the morphology of pure silica 
microparticles after release test did not show any change compared to the initial 
state. With addition of Dx, more sub-micron pores, a looser texture and large cracks 
appeared on the surface of the particles and even particle degradation was observed. 
Dx with higher molecular weight and corresponding larger molecular size contributed 
more to water channel enlargement by its dissolution, resulting in more pronounced 
acceleration of FITC-Dx 150 release. Concurrently, larger channels resulted in 
relatively looser inner structure and larger cracks, causing the particles to 
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disintegrate whereas particles containing Dx1 and Dx5 did stay intact (Fig.5). 
Meanwhile, another plausible reason for the acceleration effect of bigger Dx on the 
release could be caused by void space during the particle formation. As described by 
Vehring, the void space of spray dried particle is increased with a dimensionless 
Peclet number, Pe = R2/τdDs, where R
2/Ds is the time required for the solute to 
diffuse from the surface of the droplet to its center which is controlled by the 
diffusion rate of the solute and τd is the time required for the droplet to dry which is 
determined by the solvent evaporation rate  [27]. All generated droplets 
incorporated of different Dx ratio were atomized with same mesh and dried at the 
same conditions. In this case, only the diffusion coefficient of the solute inversely 
proportional to its hydrodynamic size influences the solute movement during the 
drying process. Thus, particles containing larger Dx show higher Peclet number, 
resulting in more void and looser inner structure, subsequently leading to faster drug 
release. Hence, Dx is a useful regulator in tailoring the release rate from silica 
microparticles. 
 
A 
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Figure.5. SEM photographs of spray-dried particles with different silica/Dx ratios at 
pH 6.0 after 7 weeks release test, (A) 5.5%:0.0%, (B) 5.0%:0.5%, (C) 4.5%:1.0%, (D) 
3.7%:1.8%, (E) 1.8%:3.7%. 
3.5. Effect of pH on release rate 
   There are two well-known stages of gelation when a silicon alkoxide is used to 
B-Dx1 B-Dx5 B-Dx60 
C-Dx1 C-Dx5 C-Dx60 
D-Dx1 D-Dx5 D-Dx60 
E-Dx1 E-Dx5 E-Dx60 
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create a sol. These two stages, hydrolysis and condensation, are tightly interlocked in 
certain systems where they occur simultaneously and less so in others where one of 
the two is relatively fast [12]. Acidic or basic conditions can be used to control the 
hydrolysis and condensation reaction. The morphology and structure of the silica 
produced by sol-gel processing can be tailored by controlling the sol-gel reaction 
kinetics, and in particular, the relative rates of hydrolysis and condensation [12]. To 
investigate the influence of processing pH on the release rate of FITC-Dx 150, the 
microparticles containing 4.5% Si/1.0% Dx 60 were fabricated at different pH. The 
morphology of particles was independent on pH values, and particles with spherical 
shape and smooth outer surface were formed in all pH conditions tested (Fig.6). The 
effect of pH of precursors on the drug release is shown in Fig.7. The initial release for 
all particles was rather similar. A complete sustained release within 35d resulted 
from particles generated at pH 6.0 while approximate 30% and 50% FTIC-Dx 150 was 
not liberated from microparticles prepared at pH 6.2 and pH 6.4, respectively. SEM 
images of the particles after release showed intact spherical shape with pores on the 
surface, illustrating the drug release, independent of pH. Possibly pH 6.0 led to the 
formation of a less dense silica network and consequently complete drug release.  
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Figure.6. SEM photographs of spray-dried particles with 4.5%silica/1.0%Dx60 at 
different pH before and after release test 
pH 6.0 before pH 6.0 after 
pH 6.2 before pH 6.2 after 
pH 6.4 before pH 6.4 after 
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Figure 7. Release of FITC-Dx150 from particles prepared with 4.5%silica/1.0%Dx60 at 
different pH 
4. Conclusion 
   A new water-soluble precursor (TMEOS) for controlled release application is 
presented. The spray-dried spherical silica particles can be fabricated at moderate 
pH and prolonged chemical reaction, organic solvents or catalyzers are not needed. 
Microparticles with either smooth or wrinkled morphologies are formed, depending 
on the amount of Dx addition. The addition of Dx significantly alters the 
microstructure of spray-dried particles, resulting in significantly faster drug release. 
Dissolution of Dx upon contact with the release medium increases the inner 
mesopore size of microparticles and provides more channels for drug diffusion, 
inducing drug molecules to be released. By increasing the Dx molecular weight to 
enlarge the water channel of silica microparticles, a sustained release of FITC-Dx 150 
with 35 days can be achieved by incorporating 1.0% Dx 60. The released amount of 
particles containing 1.0% Dx 60 decreased with increasing pH of precursor solution. 
The results demonstrate the potential to control the structure and morphology as 
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well as the sustained release behavior for high molecular weight compounds of silica 
microparticles formed via a sol-gel process with a new compatible precursor. The 
gained understanding should be very useful in designing silica-based microparticles 
for parenteral application of biopharmaceutical drugs. 
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CHAPTER 6  
Development of silica microparticles for 
sustained release of proteins with a new 
sol-gel precursor 
Abstract 
   Protein entrapment within mesoporous silica microparticles for sustained release 
application is limited by the poor water solubility and harsh processing conditions of 
traditional silica precursors. In this work, a new water soluble precursor, 
tetrakis(2-methoxyethyl) orthosilicate (TMEOS), which exhibits better 
biocompatibility with proteins, was used to fabricate microparticles to control the 
protein release via a mesoporous silica network. Two proteins, a monoclonal 
antibody IgG1 and lysozyme, were employed as the model protein drugs. The 
by-product ethylene glycol monomethylether (EGMM) from TMEOS hydrolysis 
showed high compatibility with lysozyme. The silica microparticles were prepared 
with two different spray drying systems based on two-fluid-nozzle or vibrating mesh 
nebulization or by cryomilling after a bulk gelation process. Incorporation of various 
amounts of Dextran, PEG and PVA as additive allowed to modify the protein release. 
The released amount increased with the amount and molecular weight of the 
additive. But sustained release of proteins was not achieved. The incomplete release 
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of proteins may be due to the interactions between the protein and the sol-gel silica 
matrix or a too dense network. 
Keywords: TMEOS, Sol-gel, Spray drying, Milling, Dextran, PEG, PVA, Microparticles, 
IgG1, lysozyme, Sustained release. 
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1. Introduction 
   Protein drugs are generally administrated parenterally and frequent injection 
may be required [1]. This has elicited the interest in delivery systems that can provide 
sustained release and protect sensitive protein molecules over extended periods of 
time.  
   Entrapment of proteins in microparticles using the silica sol-gel route for 
sustained release application has been rarely explored [2-4]. Protein drugs get 
encapsulated in silica microparticles upon hydrolysis and condensation of the silicate 
sol, which yields a polymeric amorphous oxo-bridged SiO2 network [5]. This provides 
high loading capacity, allows to tune pore size and may enhance protein 
stability [6-9]. However, poor water solubility of traditional silica precursors and 
harsh processing conditions of the sol-gel transition are the principal drawbacks for 
the entrapment of protein drugs [10-13]. In fact, so far there are no silica-based drug 
delivery systems on the market despite that it has shown great promises [14]. 
   Compared to conventional precursor such as tetramethyl orthosilicate (TMOS) or 
tetraethyl orthosilicate (TEOS) that involve extreme acidic or basic conditions and 
organic solvent environment detrimental to proteins [15], the new silica precursor, 
tetrakis(2-methoxyethyl) orthosilicate (TMEOS) proceeds at moderate pH and 
hydrolysis yields ethylene glycol monomethylether (EGMM) instead of methanol or 
ethanol, which is compatible with IgG1 at a low concentration. Additionally, EGMM 
with a boiling point of 124.5 °C is readily removed accompanying the water 
evaporation. Furthermore, no prolonged chemical reaction or catalyzers are needed 
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to trigger the sol-gel transition compared to tetra(2-hydroxyethyl) orthosilicate 
(THEOS). Sustained release microparticles loaded with the high molecular weight 
model compound FITC-dextran 150 were achieved via spray drying (see Chapter 5). 
Furthermore, protein stability can be assured during spray drying by selection of 
appropriate formulation and process conditions [16-18]. Consequently, this study 
aimed to develop protein loaded silica microparticles from TMEOS for sustained 
release by spray drying. For fast screening a bulk sol-gel process with subsequent 
cryo-milling was used. A monoclonal antibody IgG1 and lysozyme were employed as 
the model protein drugs. EGMM is compatible with IgG1 at the low concentrations, 
and the compatibility of EGMM was checked with another model protein lysozyme. 
The protein release from silica microparticles was tailored by changing the silica to 
additive ratio, the additive type and the molecular weight of additives. 
2. Materials and Methods 
2.1. Materials 
   Tetrakis (methoxyethoxy) silane (TMEOS) was purchased from Suzhou Chum-Win 
New Material Science & Technology Co,. Ltd., Suzhou, China. Sucrose, polysorbate 80 
(PS 80), PEG 4k, PEG 35k, PEG 1M and PVA 25k were purchased from Sigma-Aldrich, 
Munich, Germany and Dextran 60 (Dx 60) was purchased from Pharmacosmos A/S, 
Holbaek, Denmark. Solutions of 20.9 mg/mL IgG1 monoclonal antibody in 10 mM 
PBS pH 7.2 and 98 mg/mL lysozyme in 10 mM His pH 6.0 were used. Ethylene glycol 
monomethylether (EGMM, 99.5%) was supplied by the reagent center of the LMU 
Munich, Germany. All other reagents used were of analytical grade. Deionized water 
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(Milli-Q) was used for all precursor preparation. 
2.2. Methods 
2.2.1. Turbidity 
   The turbidity of lysozyme/EGMM mixtures in formazine nephelometric units 
(FNU) was determined with a NEPHLA turbidimeter (Dr. Lange, Düsseldorf, Germany), 
based on light scattering in an 90° angle at λ = 860 nm. The system was calibrated 
with a formazine standard. Approximate 2 mL of each sample were used for analysis. 
2.2.2. Light obscuration 
   Light obscuration tests were carried out according to Ph.Eur. 2.9.19. The particle 
counting of subvisible particles in a size range between 1 and 200 µm was conducted 
using a SVSS-C instrument and associated analysis software (PAMAS GmbH, 
Rutesheim, Germany). For each sample (n = 3) three measurements of a volume of 
0.3 mL with a pre-run volume of 0.3 mL at fixed fill rate, emptying rate and rinse rate 
of 5 mL/min were performed. Prior to each measurement the system was rinsed with 
high purified water until particle counts of less than 30 particles/mL were 
determined. The obtained results represented the mean value of the particle counts 
of three measurements, referred to a sample volume of 1.0 mL. 
2.2.3. High performance size exclusion chromatography (HP-SEC) 
   HP-SEC was performed on an Agilent 1100 series HPLC system (Agilent 
Technologies, Santa Clara, California, USA). The autosampler and the column were 
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temperature controlled at 20 °C and 23 °C, respectively. The samples were 
centrifuged for 5 minutes at 2000 rpm. For each sample solution, 40 µl supernatant 
were injected onto a Tosoh TSKgel® G3000SWXL column (7.8x300 mm) (Tosoh 
Bioscience, Stuttgart, Germany) using a mobile phase of 100 mM sodium phosphate 
buffer with additional 100 mM sodium sulfate pH 6.8 at a flow rate of 0.5 ml/min. 
The eluted sample was detected by UV absorption at 280 nm. The chromatograms 
were analyzed regarding retention times and the area under the curve (AUC) with 
ChemStation® B.02.01-SR2 (Agilent Technologies). 
2.2.4. Spray drying of microparticles 
   To investigate the effects of additives, different formulations were prepared 
(Table 1). The maximal TMEOS concentration of spray solution was set to 25% (equal 
to 4.5% silicon dioxide), which would yield an EGMM concentration of 5.7% upon 
hydrolysis. The total mass content of silicon dioxide and additives was set to 
5.5% (w/v). In a typical procedure, IgG1 or lysozyme solution containing sucrose and 
PS 80 was mixed with TMEOS and additive to a final volume of 10 mL (10 mM 
PBS, pH 6). Hydrolysis was performed for 2 hours. The spray drying conditions in the 
nano spray dryer Büchi-90 (Büchi Labortechnik, Flawil, Switzerland) were Tin/Tout: 
120 °C /58 °C, flow rate of drying air: 120 L/min, atomizing mesh size: 7.0 μm. Spray 
solutions were filtered through a 0.2 μm PVDF syringe filter prior to spray drying. The 
spray drying conditions in the mini spray dryer Büchi-290 (Büchi Labortechnik, Flawil, 
Switzerland) were Tin/Tout: 105 °C /73 °C, flow rate of drying air: 670 L/min, flow rate 
of feeding: 3 mL/min; nozzle size: 0.4 mm. Spray solutions were filtered through a 
0.2 μm PVDF syringe filter prior to spray drying. 
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Table 1: Formulations of precursors for spray drying 
Spray 
dryers 
TMEOS (SiO2)   
(%w/v) 
Dextran 60 
(%w/v) 
Sucrose   
(%w/v) 
PS 80   
(%w/v) 
IgG1 
(%w/v) 
Lysozyme 
(%w/v) 
 
B-90 25 (4.5) 1.0 0.5 0.1 0.42 0.0  
B-90 15 (2.8) 2.7 0.5 0.1 0.42 0.0  
B-90 12.5 (2.3) 3.2 0.5 0.1 0.42 0.0  
B-90 10 (1.8) 3.7 0.5 0.1 0.42 0.0  
B-90 25 (4.5) 1.0 0.5 0.1 0.0 0.49  
B-90 15 (2.8) 2.7 0.5 0.1 0.0 0.49  
B-90 12.5 (2.3) 3.2 0.5 0.1 0.0 0.49  
B-90 10 (1.8) 3.7 0.5 0.1 0.0 0.49  
B-290 10 (1.8) 3.7 0.5 0.1 0.42 0.0  
B-290 10 (1.8) 3.7 0.5 0.1 0.0 0.49  
2.2.5. Microparticle preparation with bulk gelation and milling 
   IgG1 or lysozyme solution containing sucrose and PS 80 was mixed with TMEOS 
and additive to a final volume of 10 mL (10 mM PBS, pH 6). The formulations were 
shown in Table 2. The solutions were kept in the oven for 2 weeks at 40 °C until they 
were completely dry and solidified. Then the dry gels were milled in a swing mill 
Retsch® CryoMill (Retsch Technology, Haan, Germany). After precooling the system 
with liquid nitrogen for 10 mins at 5 Hz, the dry gels were ground for 3 mins at 25 Hz. 
The obtained particles were collected and kept at 2-8 °C until release testing. 
Table 2: Formulations of precursors for bulk gelation and milling 
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TMEOS (SiO2)   
(%w/v) 
2.8 
2.3 
1.8 
4.5 
2.8 
2.3 
1.8 
1.8 
1.8Spray 
dryers 
PEG 4k 
(%w/v) 
PEG 35k 
(%w/v) 
PEG 1M 
(%w/v) 
PVA 25k   
(%w/v) 
Sucrose   
(%w/v) 
PS 80   
(%w/v) 
Lysozyme 
(%w/v) 
 
25 (4.5) 1.0 0.0 0.0 0.0 0.5 0.1 0.49  
10 (1.8) 3.7 0.0 0.0 0.0 0.5 0.1 0.49  
25 (4.5) 0.0 1.0 0.0 0.0 0.5 0.1 0.49  
10 (1.8) 0.0 3.7 0.0 0.0 0.5 0.1 0.49  
25 (4.5) 0.0 0.0 1.0 0.0 0.5 0.1 0.49  
10 (1.8) 0.0 0.0 3.7 0.0 0.5 0.1 0.49  
25 (4.5) 0.0 0.0 0.0 1.0 0.5 0.1 0.49  
10 (1.8) 0.0 0.0 0.0 3.7 0.5 0.1 0.49  
2.2.6. Particle morphology  
   The particles were visualized with scanning electron microscopy (SEM) using a 
Jeol JSM-6500F instrument (Jeol Ltd., Tokyo, Japan) with Inca Software (Oxford 
instruments, Oxfordshire, UK) at an accelerating voltage of 1.5 or 2.0 kV. They were 
sputtered with carbon.  
2.2.7. In Vitro release 
   The protein release was studied in PBS buffer (0.01 M phosphate; 0.138 M NaCl; 
0.027 M KCl, pH 7.4) at 37 °C using a shaking incubator (60 rpm). Approximately 
200 mg of drug-loaded particles and 1 mL buffer were placed in a 1 MDa cutoff 
dialysis bag and immersed into a 15 mL disposable plastic tube with 9 mL PBS 
containing 0.05 % NaN3. At designated time points, 1 mL of release medium were 
withdrawn and replaced with the same amount of fresh release medium. Protein was 
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quantified at 280 nm using an Agilent 8453 UV-Vis spectrophotometer (Agilent 
Technologies, Böblingen, Germany). Each experiment was performed in triplicate. 
3. Results and discussion 
3.1. Compatibility of EGMM with lysozyme 
   Hydrolysis of TMEOS generates EGMM which can evaporate with the water. It is 
important to check the compatibility of the by-product with the incorporated drug. 
We found that EGMM is compatible with IgG1 at the low concentrations. To further 
study the maximal compatibility of EGMM with proteins, lysozyme was exemplarily 
tested. All lysozyme samples showed similar visual transparency as the placebo 
samples (Fig. 1). This was consistent with the turbidity measurement and light 
obscuration. Additionally, no soluble aggregate or fragment formation of lysozyme 
samples was observed by HP-SEC analysis with 100% monomer recovery. Based on 
these results, it was concluded that high EGMM concentration (50%) is also 
compatible with lysozyme.  
 
(A) 
50% EGMM 30% EGMM 15% EGMM 10% EGMM 0% EGMM 100% EGMM 
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Fig. 1. Visual appearance of mixtures of lysozyme (A) or placebo (B) solutions with 
different EGMM concentration. A 1 mg/mL lysozyme in 10 mM PBS pH 7.4 was used. 
Table 3. Analysis of mixtures of lysozyme or placebo solutions with different EGMM 
concentration by turbidity, subvisible particle counting and HP-SEC. A 1 mg/mL 
lysozyme in 10 mM PBS pH 7.4 was used. 
Composition Turbidity 
(FNU) 
≥1 μm Particle concentration 
(#/mL)  
Monomer recovery 
(%) 
Lysozyme 0.96 5096 ± 730  
EGMM 0.49 616 ± 345  
PBS 0.58 633 ± 37  
50% EGMM 5.14 9586 ± 4089 104.2% 
30% EGMM 13.00 103544 ± 11504 102.4% 
15% EGMM 9.03 65938 ± 1948 100.7% 
10% EGMM 7.14 22388 ± 2773 101.1% 
Placebo 50% 
EGMM 
3.4 17352 ± 3325  
Placebo 30% 
EGMM 
5.45 9239 ± 2444  
Placebo 15% 
EGMM 
6.69 2056 ± 565  
(B) 
50% EGMM 30% EGMM 15% EGMM 10% EGMM 0% EGMM 100% EGMM 
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Placebo 10% 
EGMM 
3.69 2701 ± 423  
3.2. Protein release from silica microparticles  
   Similar as for model drug FITC-Dx 150, the IgG1 or lysozyme loaded silica 
microparticles were prepared with a Nano Spray Dryer B-90 using different amounts 
of Dx 60 to investigate the effect of this additive on the release profiles. IgG1 release 
was not observed from all the silica microparticles even at the highest additive 
content of 3.7% Dx 60. In contrast 3%, 14%, 31%, and 43% of lysozyme were released 
from the microparticles containing 1.0%, 2.7%, 3.2% and 3.7% Dx 60 within one week 
reaching a plateau (Fig.2 (a)). Around 15% IgG1 and 20% lysozyme were released 
within two weeks from silica microparticles of 1.8%silica/3.7%Dx 60 prepared with a 
Mini Spray Dryer B-290 (Fig.2 (b)). As the nozzle design of these two spray dryers is 
essentially different, the generation and drying process of droplets varies, which led 
to different morphologies (Fig.3) and release profiles. Absence and incomplete 
release of proteins may be related to the interactions between the protein and the 
sol-gel silica matrix [19]. Proteins exhibit an abundance of H-bonding groups on the 
surface, which result in extensive interaction with the silica polymer network. 
Furthermore, protein molecules may serve as a nucleus for the condensation 
polymerization and made become tightly entrapped by the silica gel, preventing the 
release.  
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Fig.2. Release profile of proteins from silica microparticles of different 
silica/Dx 60 ratio prepared with a Nano Spray Dryer B-90 (a) and a Mini Spray Dryer 
B-290 (b).  
    
Fig.3. SEM photographs of silica microparticles of 1.8%silica/3.7%Dx 60 prepared 
with a Nano Spray Dryer B-90 (a) and a Mini Spray Dryer B-290 (b). 
   Addition of PEG as an alternative was tested to enhance the release. Since PEG 
exhibits a low melting temperature around 60 °C, which is close to the outlet 
temperature in the spray drying, a bulk gelation process followed by cryomilling was 
utilized to fabricate the silica microparticles. The lysozyme release profiles of milled 
particles are similar to those of spray dried particles as shown in Fig.4. The released 
(a) (b) 
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amount increased with the amount of additive. An increase of PEG molecular weight 
accelerated the release when the equivalent amount of PEG was added. Addition of 
PVA showed a similar effect on lysozyme release. Overall, Dx, PEG, PVA allow to 
modify the release from the silica network but the capacity to tailor protein release is 
limited and further studies are necessary.  
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Fig.4. Release profiles of lysozyme from silica microparticles of different 
silica/additive ratio prepared via bulk gelation and cryomilling from, 
4.5%Silica/1.0%PEG 4k ■ ; 1.8%Silica/3.7%PEG 4k □ ; 4.5%Silica/1.0%PEG 35k ● ; 
1.8%Silica/3.7%PEG 35k ○; 4.5%Silica/1.0%PEG 1M ▲; 1.8%Silica/3.7%PEG 1M △; 
4.5%Silica/1.0%PVA 25k ▼; 1.8%Silica/3.7%PVA 25k ▽. 
4. Conclusion 
   The by-product EGMM produced in the course of TMEOS hydrolysis exhibited 
high compatibility with lysozyme and is readily removed accompanying the water 
evaporation, which holds great promise for the TMEOS applications. The silica 
microparticles were developed with two spray dryers and a bulk gelation and 
cryomilling using a monoclonal antibody IgG1 and lysozyme as model proteins. 
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Incorporation of Dx 60, PEG and PVA into the silica microparticles modified the 
release but did not render tailor made sustained release. Only a fraction of protein 
was released within a few days. Generally, the released amount increased with the 
amount and molecular weight of the additive. The incomplete release may result 
from the interactions between the protein and the sol-gel silica matrix or a too dense 
network. Although well controlled release could not be achieved in this study, 
TMEOS as a potential silica precursor should be further studied for protein drug 
delivery testing some other additives and reaction conditions.  
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CHAPTER 7  
Summary of the thesis 
   Protein drugs have emerged as promising therapeutic agents for treatment of 
various severe conditions in recent years. They are generally administrated by 
injection due to rapid degradation by proteolytic enzymes in the gastrointestinal and 
poor transport across the biological barrier. For treatment of chronic diseases 
repeated injections are necessary in order to achieve therapeutic drug levels 
reducing patient compliance. Triglycerides and silica-based microparticles have 
drawn increasing attention to control the sustained release of protein 
drugs (Chapter 1). In this thesis, triglyceride coated polyol core as well as silica 
microparticles for sustained release of proteins were formed by fluid bed coating and 
spray drying, respectively.  
   Lipid coating of such small microparticles is challenging owing to the high 
tendency to agglomerate formation upon coating with the tacky lipid. Therefore, in 
Chapter 3, optimal process parameters for hard fat and glyceryl stearate coated 
microparticle preparation without agglomeration at modest temperature were 
established in a Mini Glatt fluid bed system. 30 g drug loaded mannitol carrier 
microparticles were coated with 5 g, 10 g, 20 g and 30 g lipids, respectively. Placing 
more lipid onto the microparticles reduced both burst and release rate, and the 
particles maintained their geometric form during the release test. The model drugs 
methyl blue and aspartame were completely released in vitro through pores which 
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mainly resulted from dissolution of the polyol core beads. The release of methyl blue 
and aspartame was extended up to 25 and 7 days. Burst and release rates were 
similar for hard fat and glyceryl stearate. Polymorphic transformation of the hart fat 
was observed upon release. The reduction in size of starting bead showed only 
marginal effect on the drug release behavior. In contrast, the release of the more 
hydrophilic model compound was much faster than that of the less hydrophilic. The 
formulation and manufacturing parameters for the design of sustained release 
microparticles were subsequently transferred to a monoclonal IgG1 antibody. 
   Although lipid coated polyol core microparticles are promising depot formulation 
for protein drugs, the retention of protein stability during microparticle fabrication is 
still a major concern. In order to prevent IgG1 unfolding at the air-liquid interface and 
subsequent aggregation, the protein was stabilized with 22.5 mg/mL sucrose, 
0.1% PS 80, 10 mM methionine in 10 mM His buffer pH 7.2 during the spray loading 
process in Chapter 4. Protein loaded mannitol carrier microparticles were coated 
with the two lipids. An extended release over 6 weeks could be achieved by 30 g 
hard fat coating. The IgG1 was released in its monomeric form and maintained its 
secondary structure as shown by FTIR. Sustained release of IgG1 was not observed 
from glyceryl stearate coated microparticles, which may result from the lack of large 
pores in the glyceryl stearate layer or detrimental surfactant character of glyceryl 
stearate.  
   Owning to poor water solubility of conventional silica precursors, organic solvent 
and extreme conditions of pH and high temperature are often needed to achieve a 
uniform sol, conditions which are unfavorable for the encapsulation of protein drugs. 
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A new water soluble precursor, TMEOS, for controlled release application was 
presented in Chapter 5. The hydrolysis of TMEOS yields ethylene glycol 
monomethylether (EGMM), which is compatible with IgG1 at a low concentration 
and readily removed accompanying the water evaporation (boiling point 124.5 °C). 
The spray dried spherical silica particles were fabricated at moderate pH and 
prolonged chemical reaction, organic solvents or catalyzers were not needed. 
Different quantities of dextrans with varying molecular weight were incorporated 
into the silica microparticles to the tailor release profile of a high molecular weight 
model compound, FITC-dextran 150. Microparticles with either smooth or wrinkled 
morphologies were formed, depending on the amount of dextran addition. 
Dissolution of dextrans upon contact with the release medium increased the inner 
mesopore size of the microparticles and provided more channels for drug diffusion, 
inducing drug molecules to be released. The release increased with the amount and 
molecular weight of added dextran. A sustained release over 35 days was achieved 
with addition of 1.0% dextran 60 kD. The rate of FITC-dextran 150 release from the 
dextran 60 containing particles decreased with higher precursor solution pH. The 
gained knowledge was subsequently applied in the proteins to control the sustained 
release. 
   Protein loaded silica microparticles from TMEOS for sustained release application 
were prepared by spray drying or cryomilling after a bulk gelation process in 
Chapter 6. EGMM exhibited high compatibility with lysozyme. Incorporation of 
various amounts of dextran, PEG and PVA as additive slightly modified the protein 
release. The released amount increased with the amount and molecular weight of 
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the additive. But sustained release of proteins was not achieved. The incomplete 
release may result from the interactions between the protein and the sol-gel silica 
matrix or a too dense network.  
   In summary, this work focused on the sustained release control of proteins based 
on triglycerides and silica based materials. Hard fat coated polyol core microparticles 
showed high potential for protein delivery. Although well controlled release of 
proteins was not achieved from silica microparticles, TMEOS as a potential silica 
precursor should be further studied by testing some other additives and reaction 
conditions. Both of them provide interesting and useful information for future 
protein drug delivery. 
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